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ABSTRACT 
 
Katelyn Patricia Reighard:  Antibacterial and Biophysical Characterization of Nitric Oxide-
Releasing Chitosan Oligosaccharides - Towards a New Cystic Fibrosis Therapeutic. 
(Under the direction of Mark H. Schoenfisch) 
 
Cystic fibrosis (CF) is characterized by chronic infections within the highly viscous mucus 
layer of the airways.  Nitric oxide (NO), an endogenously produced free radical involved in the 
immune response to foreign pathogens, can be delivered exogenously from macromolecular 
scaffolds to combat bacterial infection.  Herein, the ability of NO-releasing chitosan 
oligosaccharides to eradicate P. aeruginosa biofilms and alter the biophysical properties of 
infected airway mucus was characterized. 
As oxygen gradients form within the CF mucus layer, the antibacterial efficacy of NO was 
determined in aerobic and anaerobic conditions.  Against planktonic cultures, NO-releasing 
chitosan oligosaccharides were more effective antibacterial agents under anaerobic environments 
due to reduced NO reactions with oxygen.  However, the bactericidal NO dose released from the 
scaffold was the same under both conditions, indicating that the efficacy of NO against planktonic 
cultures was independent of oxygen concentration.  For P. aeruginosa biofilms, the minimum 
biofilm eradication concentration of NO-releasing chitosan oligosaccharides was decreased under 
anaerobic conditions.  Furthermore, the concentration of NO required to eradicate biofilms was 
10-fold lower than tobramycin under anaerobic conditions. 
Biofilm disruption and eradication were investigated as a function of NO-releasing 
chitosan oligosaccharide dose, with results compared to non-NO-releasing chitosan 
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oligosaccharides and tobramycin.  Quantification of biofilm expansion/contraction and multiple-
particle tracking microrheology were used to assess the biofilm structural integrity before and after 
antibacterial treatment.  While tobramycin had no effect on the physical properties of the biofilm, 
NO-releasing chitosan oligosaccharides induced biofilm degradation.  Control chitosan 
oligosaccharides actually increased biofilm elasticity, indicating that the scaffold may mitigate the 
biofilm disrupting power of NO. 
The effects of NO on the physical properties of CF mucus were examined to assess the 
mucolytic potential of NO-releasing chitosan oligosaccharides.  When released from a 
mucoadhesive scaffold, NO increased mucin migration during electrophoretic separation, 
indicating a reduction in mucin molecular weight.  Additionally, NO destroyed the physical 
structure of mucin networks and reduced the viscosity and elasticity of CF sputum.   The 
mucoadhesive properties of each scaffold dictated the mucolytic efficacy of NO-releasing chitosan 
oligosaccharides, as non-adhesive scaffolds were incapable of altering mucins in purified mucin 
solutions and CF sputum. 
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CHAPTER I:  INTRODUCTION 
1.1 Cystic Fibrosis  
Cystic fibrosis (CF) is a life-limiting, genetically inherited disorder affecting 30,000 people 
in the United States of America (US) and 70,000 people worldwide.1-2  This disease is caused by 
mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator 
(CFTR) protein, which in turn controls mucus and ion transport.3-5  Defects in the CFTR protein 
result in accumulation of mucus throughout the body and obstruction of normal function in the 
liver, pancreas, gastrointestinal tract, and the reproductive system.  However, buildup of mucus is 
most damaging in the respiratory system.  In healthy airways, CFTR controls the absorption of 
chloride, sodium, and water across the epithelium surface. Disruption of CFTR function associated 
with CF results in dehydration of the airway surface liquid (ASL) and excessive absorption of 
sodium and chloride ions.  Depletion of the ASL causes the collapse of cilia, impeding their 
movement and thus inhibiting mucociliary clearance.6   Goblet cells in the CF airway continue to 
secrete mucus, further intensifying the problem.  As mucus accumulates and thickens in the CF 
airway, the bronchial tubes become obstructed, fostering a suitable environment for bacteria 
colonization.  Bacteria are protected from the immune response by the thickened mucus layer and 
formation of biofilms.6  Chronic infections develop, causing increased inflammation and 
degradation of lung health over the lifespan of the patient.6  Respiratory complications of these 
chronic infections ultimately result in the death of 85% of patients with CF.7 
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1.1.1 Innate airway defense in healthy lungs 
 Adult humans inhale over 1,000 liters of air per day with near constant microbe exposure.8  
To combat this, the human airway has developed an innate defense that operates via two 
mechanisms: the development of a “chemical shield” and the mechanical clearance of foreign 
particles (i.e., mucociliary and cough clearance).   While some controversy over these two 
mechanisms exists, it is generally recognized that mechanical clearance is more important to 
preventing microbial colonization.9 
 The chemical shield hypothesis as a mechanism for innate airway defense was first 
proposed in the mid-1990s.  It suggests that inhaled bacteria are eradicated by antimicrobial 
proteins and peptides such as lysozyme, lactoferrin, and antiporoteases, and defensins in the 
ASL.10-13   Many of these molecules are thought to be salt-sensitive and only effective in low salt 
environments (i.e., < 50 mM sodium chloride).12,14-15  It is believed that the airway epithelium 
regulates ionic composition of the ASL to specifically enhance the activity of these antimicrobial 
proteins and peptides.16 
 The predominant hypothesis of how the innate airway defense functions is mechanical 
clearance. Bacteria and other foreign particles are physically removed by the flow of mucus in the 
airway as shown in Figure 1.1  In healthy airways, the ASL consists of two components: the mucus 
layer and the periciliary layer (PCL).  The mucus layer consists primarily of high molecular weight, 
glycosylated macromolecules called mucins that exhibit an immense diversity of carbohydrate side 
chains, allowing mucins to adhere to and entrap a wide range of particles. 17-18  Mucins form a gel 
with turbulent flow that promotes the enmeshment of particles in the tangled mucin network.  
Below the mucus layer is the PCL (Figure 1.1) serving two primary functions.  First, the low 
viscosity of this layer provides an appropriate media for coordinated ciliary movement, with the  
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Figure 1.1 In healthy airways, cilia within the hydrated periciliary layer (PCL) beat in a 
coordinated fashion resulting in mucus flow.   Foreign particles entrapped in the mucus layer 
are removed via this mucociliary transport. 
Mucus Layer
PCL
Epithelial Cells
60 µm/s
Goblet Cells
Foreign Particles
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thickness of the PCL directly correlated with cilia height (approximately 7 µm in healthy 
airways).19   Secondly, this layer separates and protects the epithelial cell surface from the mucus 
layer.   
Mucociliary clearance requires both a healthy mucus layer and PCL.  To move the mucus 
layer, cilia beat in a coordinated power stroke.  During this step, the cilia fully extend and exert 
force on the undersurface of the mucus layer.  Friction between the PCL and the mucus layer 
causes the PCL to move with the mucus layer.20   During the recovery stroke, cilia slowly return 
to their initial position, bending as to not interact with the mucus layer.  The recovery stroke does 
not affect ASL movement.21  In this concerted manner, the cilia move mucus and entrapped foreign 
particles up and out of the airway via the larynx.  
 In order to maintain both the chemical and mechanical mechanisms for airway defense, the 
ionic strength and volume of the PCL must be carefully regulated.  The PCL thickness is 
maintained by sodium (Na+) and chloride (Cl-) ion absorption through the airway epithelial cells.22  
When the PCL is too large, the cilia do not reach the mucus layer during their power stroke, 
inhibiting mucus transport (Figure 1.2-A).  In this situation, the epithelial Na+ channel (ENaC) is 
highly active, resulting in absorption of Na+ and subsequent cellular water intake with PCL 
dehydration.  Conversely, cilia movement is inhibited when the PCL is too thin, as they require 
low viscosity solutions to beat effectively (Figure 1.2-B).9  To remedy this, ENaC is inhibited, 
changing the cell membrane potential and causing the secretion of Cl- and water.  In addition to 
ion transport, the mucus layer can swell and shrink to release extra liquid into the PCL, helping 
maintain adequate PCL volume for ciliary movement.23  
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Figure 1.2 Maintenance of PCL volume in healthy airways.  (A) When the PCL is too 
thick, beating cilia do not reach the mucus layer and therefore cannot move it.  To remedy 
this, Na+ absorption is mediated via the ENaC channel, resulting in water absorption.  (B) 
Alternatively, a dehydrated PCL impairs mucus movement by preventing ciliary movement, 
which is fixed in healthy airways by increasing Cl- and water secretion into the PCL via 
ENaC inhibition. 
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1.1.2 Innate airway defense in CF   
 Disturbances in ion transport in the CF airway result in dehydration of the ASL and 
increased salt content.   In the chemical shield hypothesis, the high salt concentration of the CF 
airways are purported to render the salt-sensitive antimicrobial peptides and defensins 
ineffective.11   However, this hypothesis has largely been discredited as  the activities of the most 
predominant antimicrobial molecules (i.e., lactoferrin and lysozyme) were found to be salt-
insensitive.24  Additionally, ion concentrations of ASL in the upper and lower airways in both CF 
and non-CF subjects were found to have similar salt concentrations.25-26  In light of this evidence, 
the role of salt concentrations in the ASL is believed to be insignificant in CF pathogenesis.   
With this knowledge, deficiencies in CF bacterial clearance can be largely explained by 
defective mechanical clearance as shown in Figure 1.3.  As cilia require the low viscosity of the 
PCL in order to beat properly, depletion of the PCL results in cessation of mucociliary clearance.19   
The CF airways cannot restore the PCL via secretion of water due to defects in the CFTR.  
Furthermore, the loss of the PCL also results in adhesion of the mucus layer to the airway surface, 
greatly reducing the efficacy of mucus clearance by coughing.27  This process is compounded by 
the continual secretion of mucins by goblet cells, resulting in the accumulation of mucus in the 
airways (Figure 1.3).  
1.1.3 Bacterial lung infections in CF 
 Lung degradation due to chronic bacterial infections account for 80–95% of CF-deaths.7   
As such, understanding the microbial ecology of the CF lung is vitally important to developing 
therapeutics.  Over the lifespan of a patient, the bacteria strains found in the CF airways change 
(Figure 1.4).28  In children, Staphylococcus aureus (S. aureus) and Haemophilus influenzae (H. 
influenza) colonization are most common, but these bacterial strains are associated with low  
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Figure 1.3 Loss of mucociliary clearance in CF airways. 
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morbidity rates compared to other strains (e.g., Pseudomonas aeruginosa and Burkholderia 
cepacia).7  While S. aureus isolates are frequently found in sputum cultures, they are believed to 
exist primarily in the nasal and upper respiratory tract where their presence is considered benign.7  
However, methicillin-resistant strain colonization has increased in the US over the last 10 years, 
indicating that emerging drug resistance might increase the toxicity of this pathogen.29 
Despite low rates of colonization at all ages, the bacteria in the Burkholderia cepacia  
complex (BCC) are linked to high incidences of mortality (3.1% in 2005).30  The BCC is comprised 
of at least 17 closely related Gram-negative bacteria species that are intrinsically resistant to 
antibiotics and disinfectants.31  One source of this innate resistance is the unusual chemical 
structure of lipopolysaccharides in the cell membranes of BCC organisms that consist of fewer 
phosphate groups than typical lipopolysaccharides.32  The reduced number of anionic phosphate 
groups renders the bacteria resistance to cationic antibiotics (e.g., aminoglycosides and 
polymyxins).32  As a result, BCC infections are often treated with combination therapies based on 
data from multiple combination bactericidal antibiotic tests (MCBT or “checkerboard” assays).33  
Unfortunately, this type of testing and therapy did not improve clinical or bacteriological outcomes 
in a recent clinical trial.34  Due to the seriousness of these infections, patients colonized with BCC 
organisms are isolated from other patients and ineligible for lung transplants.30 
The bacteria most associated with morbidity and mortality in the CF population is P. 
aeruginosa.35  While P. aeruginosa colonization rates are low in children, the prevalence of P. 
aeruginosa in the adult CF population is over 80%, making it a nearly universal problem for all 
patients (Figure 1.4).  Additionally, adults are colonized by an average of 2.38 phenotypically 
distinct P. aeruginosa isolates at any given time.36  One of the main causes for the pathogenicity 
of P. aeruginosa is its ability to genetically adapt to the CF lung in order to evade the host immune  
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Figure 1.4 Colonizing microbes in CF patients in the US.  Reprinted with permission 
from the 2013 Patient Registry Annual Data Report to the Center Directors (CF Foundation). 
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response and antibiotic therapy.  These adaptations will be outlined in the Section 1.1.4.  As P. 
aeruginosa is considered the most clinically important pathogen when treating CF, this dissertation 
research will focus on P. aeruginosa.   
1.1.4 Adaptations of P. aeruginosa to the CF airway 
The progression of P. aeruginosa colonization to chronic infection as a result of the CF 
mucus environment is outlined in Figure 1.5 (adapted from Worlitsch et al.37 and Hassett et al.6).   
Inhaled, nonmucoid P. aeruginosa respire aerobically and are generally susceptible to antibiotics.  
In healthy airways, these bacteria are easily removed by mucociliary clearance, as shown in Figure 
1.1.  In CF airways, depletion of the PCL and accumulation of a highly viscous mucus layer impairs 
mucociliary clearance (Figure 1.3).  Under these conditions, inhaled P. aeruginosa utilize their 
flagella and pili to actively penetrate the mucus layer and move to low oxygen zones (Figure 1.5-
A).38  Once inside the hypoxic or anaerobic plaques of CF mucus, the nonmucoid P. aeruginosa 
undergo several mutations.   Bacteria switch from aerobic to less efficient anaerobic respiration 
and slower growth modes (Figure 1.5-B).37,39  As most antibiotics (e.g., aminoglycosides, third 
generation penicillins, and fluoroquinolones) exhibit better eradication against rapidly dividing 
bacteria, the switch to anaerobic respiration decreases P. aeruginosa susceptibility.6  Conversion 
to anaerobic metabolism is concomitant with a change to the mucoid phenotype (Figure 1.5-B), a 
factor that also increases antibiotic resistance.37  This phenotype is characterized by mutations in 
the mucA22 gene, loss of flagella, and the formation of a protective alginate capsule.40 As flagella 
stimulate the host immune response, their removal is a mechanism of evasion.41 The low oxygen 
conditions of CF mucus stimulate the production of alginate, an exopolysaccharide (EPS) that 
forms an extra protective capsule around the bacteria, further increasing protection from antibiotics 
and the host immune response.37 
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Figure 1.5 Adaptation of P. aeruginosa to the CF airways. 
Nonmucoid
P. aeruginosa
+
-
O2
Gradient
Mucoid P. aeruginosa
+
-
O2
Gradient
+
-
O2
Gradient
P. aeruginosa Biofilm
12 
 
 The final and most successful P. aeruginosa adaptation to the CF airway is the 
development of bacterial biofilms (Figure 1.5-C).39  Biofilms are cooperative communities of 
bacteria encapsulated by a thick EPS matrix that provides additional protection from the host 
immune response and antibiotics.   Bacterial metabolism within biofilms is slowed, further 
reducing the efficacy of most antibiotics.39  Pseudomonas aeruginosa within biofilms develop 
genetic adaptations that make them resistant to antibiotics, including modification of 
lipopolysaccharide (LPS) secretions and drug efflux pumps.42  In the CF airways, P. aeruginosa 
biofilms frequently develop mutations in the lasR gene, which controls quorum sensing and the 
formation of acute virulence factors.42-44  By reducing their virulence, these mutants effectively 
“hide” from the host immune system, reducing the immune response, and initiating chronic 
infection.  
1.2 Treatment of Cystic Fibrosis 
Despite significant advances in research, CF remains a disease with no cure.  Most 
therapeutics have focused on treating the symptoms of the disease as it progresses (Figure 1.6).  
As disease pathogenesis is rooted in deficient or defect CFTR proteins, CFTR modulators are 
employed to slow CF progression.  Unfortunately, CFTR modulators are only available to a small 
percentage of CF patients, as will be discussed in Section 1.2.1.  As highly viscous mucus 
accumulates in the airways, hypertonic saline and mucolytic agents are utilized to rehydrate the 
airway and decrease mucus viscoelasticity.  If these treatments do not sufficiently improve 
mucociliary clearance, bacterial infection and inflammation develop, necessitating the need for 
antibiotic and anti-inflammatory agents.  When all other treatment options have failed, lung 
replacement is necessary for patients with advanced lung disease.  Together, improvements in  
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Figure 1.6 Therapeutics associated with CF.  As symptoms develop in CF, different 
treatment options mitigate each new symptom. 
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these treatments have raised the life expectancy of CF patients from 28 years in 1988 to 38 years 
in 2012.28 
1.2.1 CFTR modulators 
While most therapeutics (e.g., mucolytics, antibiotics, and hypertonic saline) treat the 
symptoms of CF, CFTR modulators aim to correct the underlying cause of the disease (i.e., defects 
in the CFTR protein).  Currently, Kalydeco (generic name Ivacaftor) is the only CFTR modulator 
approved for the treatment of CF.45  Kalydeco is a CFTR potentiator that repairs the function of 
the CFTR protein in people with the G551D CFTR mutation.46  Approval of this drug by the US 
Food and Drug Administration (FDA) in 2012 was extremely exciting; however, the G551D gene 
is only found in 4-5% of patients with CF.47  While this drug is highly effective for a small portion 
of the CF population, the occurrence of over 1800 mutations in the CFTR gene make development 
of gene modulators for a majority of CF patients highly unlikely.48 
1.2.2 Drugs enhancing mucociliary clearance: Inhaled saline and mucolytics 
 The primary step in CF disease pathogenesis is the development of a dehydrated, highly 
viscous ASL that prevents mucociliary clearance and leads to airway obstruction, infection, and 
inflammation.  Therefore, one of the key steps in treating CF is restoration of mucociliary 
clearance.    To this end, inhalation of hypertonic saline is prescribed to hydrate the ASL while 
mucolytic therapies aim to reduce mucus viscosity.  Hypertonic saline inhalation has been shown 
to increase mucus transport49-51 and cough clearance52 in patients with mucociliary dysfunction.  
The exogenous addition of water to the ASL improves lung function and decreases pulmonary 
exacerbations.53-55  In a long-term study where CF patients inhaled hypertonic saline twice daily 
for 48 weeks, dramatic improvements were seen in lung function (as measured by increased lung 
forced vital capacity) and a reduction in pulmonary exacerbations compared to non-treated groups 
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over the course of the trial.55  Of note, the benefits of this therapy are acute and disappear within 
24 h of administration, necessitating daily maintenance.52   
 Mucolytics are designed to decrease the viscoelasticity of the mucus layer, thereby 
improving mucociliary clearance.  Currently, dornase alfa, a highly purified solution of 
recombinant human deoxyribonuclease I (rhDNase I) is the only FDA-approved mucolytic to treat 
CF.  Dornase alfa (proprietary name Pulmozyme), reduces mucus viscosity by cleaving DNA 
strands in the ASL, decreasing their entanglement, and reducing mucus viscoelasticity.  The use 
of dornase alfa as a mucolytic in CF has been linked to improved lung function and reduction in 
pulmonary exacerbations via the removal of hyperviscous airway secretions.56-57  In reviewing 19 
studies consisting of more than 3,000 patients, the CF Foundation concluded that dornase alfa 
treatment provided a significant improvement in patient health over placebos and highly 
recommends its use for patients with moderate to severe lung disease.58 The European Cystic 
Fibrosis Society currently recommends that all CF patients ≥ 6 years old  receive treatment with 
dornase alfa regardless of lung function.59  As such, dornase alfa is one of the most successful and 
a highly recommended therapeutics for managing CF.   
 N-Acetylcysteine (NAC) has also been studied as a potential mucolytic agent. The 
mucolytic mechanism of NAC is to reduce mucin molecular weight by breaking disulfide bonds 
within the polymer and replacing it with a sulfhydryl group.60  In this way, the long mucin 
polymers are disrupted and the overall viscosity of the mucus layer is reduced.  In in vitro studies 
of mucin solutions, NAC greatly reduces the viscosity of the solution; however, its efficacy has 
never been proven in clinical trials.61  Additionally, NAC is poorly tolerated and incompatible with 
aminoglycoside antibiotics.  Thus, it has not been recommended for the treatment of CF.62 
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1.2.3 Anti-inflammatory treatment 
 Inflammation represents a chronic and serious component of CF pathogenesis.  As shown 
in Figure 1.6, airway obstruction, infection, and inflammation are involved in a perpetual cycle.  
Bacterial infections trigger inflammation as part of the host immune response.  In turn, byproducts 
of the inflammatory response stimulate mucus secretion, further decreasing the ability of the 
airways to remove the infection.  Administration of anti-inflammatory therapeutics interrupts this 
cycle and reduces lung degradation.63  Ibuprofen is currently the only anti-inflammatory 
therapeutic that has been clinically proven to improve lung function over a two year period.  
Unfortunately, ibuprofen exhibits reduced efficacy in adults and children over the age of 13, 
indicating that it is more effective at slowing disease progression than reversing it.58,64 
1.2.4 Antibiotics 
 As lung damage resulting from chronic bacterial infection is the leading cause of morbidity 
and mortality in patients with CF, effective antibiotic treatments are essential to maintaining lung 
function and patient quality of life.65-67  Due to the large variety of antibiotics available, such 
therapeutic intervention is tailored to the species of colonizing bacteria (e.g., P. aeruginosa, B. 
cepacia, S. aureus) and the severity of the infection.   
 Current antibiotic treatment regimens for CF have two primary goals:  eradicate early 
colonization and manage chronic infections.  Early eradication is essential to delay chronic 
infection and prevent deterioration of lung function.  During the early stages of colonization, P. 
aeruginosa are easier to eradicate as they have not yet fully adapted to the CF airways as outlined 
in Section 1.1.4.  Aggressive antibiotic treatment is therefore warranted in the early stages of 
colonization.   Alternatively, treatment of chronic infections is aimed at reducing exacerbations 
caused by bacterial infection and improving lung function as eradication is unlikely.58 
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For both initial colonization and chronic infections, developments in antibiotic treatments 
over the last decade have focused on improving the delivery of approved antibiotics rather than 
development of new classes of antibiotics.65  By developing inhalable formulations of antibiotics, 
the effective dose in the airways can be increased dramatically (Table 1.1).  As a result of increased 
drug concentration at the site of infection, inhalable antibiotics exhibit improved efficacy in vivo.  
This attribute was first proven with aerosolized formulations of carbencillin and gentamicin.68  
Localized delivery of antibiotics to the lungs decreased both systemic absorption and the risk of 
toxicity. 
 Tobramycin was the first FDA approved aerosolized antibiotic for CF.  Prior to the 
development of inhalable formulations, tobramycin was administered intravenously as it does not 
pass through the gastrointestinal tract.  Development of a nebulized form of tobramycin  (i.e., 
tobramycin inhalation solution or TOBI) increased the concentration of tobramycin in sputum by 
two orders of magnitude while simultaneously decreasing the concentration in blood.69  The 
delivery of tobramycin to the CF airways was further improved by the development of a dry 
inhalation powder.  Administration of tobramycin via dry powered inhalation increased 
tobramycin concentrations in CF sputum by 3 orders of magnitude compared to intravenous 
administration (Table 1.1).69     
 Inhalation of tobramycin is currently the most highly recommended treatment for 
eradication of initial P. aeruginosa colonization and maintenance of lung health after the 
development of chronic infections.  The CF Foundation recommends inhalable tobramycin doses 
of 300 mg to be administered twice daily for 28 days.62,70  During early colonization, 
administration of additional antibiotics either by inhalation, ingestion, or intravenously is 
recommended if tobramycin fails to eradicate P. aeruginosa from the airways.   
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Table 1.1    Antibiotic concentrations in serum and sputum.  Adapted from Chmiel et al. 
Drug Formulation Dosage 
Mean Peak Serum 
Concentrations 
(µg/g) 
Mean Peak Sputum 
Concentration 
(µg/g) 
Tobramycin    
       Intravenous 8 mg/kg/d 29.4 (range 23.1-35.5) 3.88 (range 1.8-5.7) 
       Nebulized Solution 300 mg 1.04 ± 0.58 737 ± 1028 
       Inhalable Powder 112 mg 1.02 ± 0.53 1048  ± 1080 
Aztreonam    
       Intravenous 2 g 80.1 5.2 
       Nebulized Solution 75 mg 0.622 (range 0.31-1.7) 537 (range 0.2-3010) 
Levofloxacin    
      Oral 500 mg 6.5 5.1 
      Nebulized Solution 240 mg 1.71 ± 0.62 4691  ± 4516 
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 Due to the success of inhalable tobramycin formulations, other antibiotics have been 
adapted for inhalation.  Since 2007, inhalable azithromycin has been highly recommended by the 
CF Foundation for the management of chronic P. aeruginosa infections.58,62  A nebulized 
formulation of aztreonam lysine, marketed under the name Cayston (Gilead, Seattle, WA) was 
approved in 2010. 71   By 2013, the CF Foundation recommended inhalable aztreonam for the 
treatment of chronic P. aeruginosa infections in patients with severe to moderate lung disease.58  
Both inhalable tobramycin and aztreonam solutions are currently still in clinical trials to optimize 
dosages and treatment regimes.72 As lung infections are the primary cause of morbidity and 
morality in CF patients, the development of new antibacterial treatments is crucial to improving 
quality of life and expanding life expectancy.65-67  Additionally, expansion of research into non-
conventional antibiotics aimed at eradicating bacteria in the biofilm mode of growth is necessary 
as antibiotic resistance continues to be problematic, particularly for CF.73 
1.2.5 Lung transplantation 
 When all other treatment options have failed, lung transplants are required to replace the 
weakened and diseased lungs of CF patients.  Lung transplants are not a cure for CF— they are 
only considered for patients with advanced lung disease.  In addition to the risk associated with 
serious surgery, the immunosuppressive drugs required post-transplantation weaken the immune 
system of the patient and leave them vulnerable to infection.  In CF, immunosuppression is 
particularly harmful as infection is the leading cause of mortality. In fact, these hazards are so great 
that it is unclear if lung transplantation benefits children with CF.74  These factors along with the 
low supply of donor organs mean this treatment will always be limited to end of life care.  In 2012, 
only 205 patients in the US received lung transplants.28 
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1.3 Nitric Oxide  
 Nitric oxide (NO) is an endogenously produced, highly reactive free radical involved in a 
wide variety of physiological processes.   In normal function, NO is produced by endothelium NO 
synthase (eNOS) and neuronal NO synthase (nNOS) at low concentrations (pM-nM) to regulate 
processes such as vasodilation, angiogenesis, and neurotransmission.75-77  Larger concentrations 
(µM) are produced by inducible NO synthases (iNOS) as an antimicrobial in macrophages and 
neutrophils in response to bacterial colonization and infection.78  As the antimicrobial properties 
of NO are essential to developing a CF therapeutic, further details are provided below. 
1.3.1 Molecular targets of NO antimicrobial activity 
 Nitric oxide is a broad-spectrum antimicrobial molecule capable of eradicating bacteria, 
biofilms, and fungus.78-79  The bactericidal activity of NO is complex and multi-mechanistic 
(Figure 1.7).79-80  Due to its uncharged, lipophilic state, NO can readily penetrates bacteria cell 
membranes and exerts both extracellular and intracellular stresses.  Many of NO’s bactericidal 
mechanisms involve the formation of reactive intermediates.81  The reaction of NO with oxygen 
and superoxide results in the formation of peroxynitrite (-ONOO), nitrogen dioxide (NO2), and 
dinitrogen trioxide (N2O3).  Of note, some of these congener molecules, especially peroxynitrite, 
are more potent antimicrobials than NO alone.79   
The molecular targets of NO and its reactive intermediates include DNA, lipids, thiols, 
heme-containing proteins, and metalloenzymes.  The main bactericidal mechanism of NO is 
indirect deamination of DNA by the reactive N2O3 intermediate.
82-83  Additionally, -ONOO and 
NO2 have been linked to DNA strand breaks and abasic site formation.
79,84  Lipid peroxidation has 
been noted as another primary source of NO’s toxicity and is mediated by both -ONOO and NO2.78   
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Figure 1.7     Antimicrobial reactions of NO with likely mechanisms of action.  Nitric Oxide 
reacts with oxygen and superoxide to form reactive intermediates (e.g., N2O3, ONOO-).  
Together these molecules exert oxidative and nitrosative stresses on bacteria.  Reprinted with 
permission from Hetrick et al.81 
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Protein deactivation can occur either by S-nitrosylation of sidechain thiols or NO binding 
to the Fe(II) centers in heme-containing proteins.79,85  For proteins that contain iron-sulfur clusters, 
reaction with NO causes release of iron and subsequent loss of protein function.79,85  Deactivation 
of these enzymes impairs nearly every cellular process including metabolism, respiration, RNA 
modification, and DNA repair and replication. 
Due to multi-mechanistic antimicrobial activity, NO exhibits killing action against both 
Gram-positive and Gram-negative bacterial strains.86-87  Gram-positive species such as S. aureus 
are generally believed to be less susceptible to NO than Gram-negative species due to their thick, 
protective peptidoglycan membrane layer.78,81  Nevertheless, successful eradication of S. aureus 
in both planktonic and biofilm states has been demonstrated, albeit at greater concentrations.88-90   
Nitric oxide is effective at eradicating methicillin-resistant S. aureus (MRSA),91-92  which holds 
particular importance as MRSA infections continue to rise in the CF community (Figure 1.4), 
necessitating the development new broad-spectrum antimicrobial treatments. 
Pseudomonas aeruginosa, a Gram-negative pathogen, is particularly susceptible to NO-
mediated eradication.78,81,87,93-99  As the pathogen most associated with lung degradation and 
eventual death,35 eradication of P. aeruginosa is particularly important in the context of CF.  
Unfortunately, P. aeruginosa eradication by NO has only been reported under aerobic conditions, 
78,81,87,93-99   which do not adequately the environment of the CF mucus layer (Section 1.1.4). As 
shown in Figure 1.8, P. aeruginosa both produces and consumes NO as part of its metabolic cycle 
during anaerobic growth.6,39,100  Located in the bacterial cytoplasmic membrane, nitrate reductase 
enzymes (NAR) reduce nitrate (NO3
-) to nitrite (NO2
-), which is quickly moved to the periplasmic 
space between the inner and outer membrane via NarK2 efflux pumps.  In the periplasm, NO2
- is  
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Figure 1.8 Anaerobic respiration of P. aeruginosa.    
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further reduced via nitrite reductase (NIR) to NO.  Complementary to its generation, NO is 
eliminated from the cell by nitric oxide reductase (NOR) to yield N2O.  In the final stage of 
denitrification, N2O is reduced to N2 by nitrous oxide reductase (N2OR) subsequently diffuses out 
of the cell.  During this process, NIR and NOR act in concert so that NO levels do not exceed 65 
nM.101-102 While NO-releasing therapeutics are generally effective against P. aeruginosa, the 
ability to enzymatically reduce NO may alter the antibacterial efficacy in anaerobic or low oxygen 
conditions (e.g., CF mucus). 
1.3.3 Anti-biofilm efficacy of NO against P. aeruginosa  
In addition to being toxic to planktonic bacteria, NO has been shown to both disperse and 
eradicate P. aeruginosa biofilms.  Biofilm dispersal is a naturally occurring phenomenon that 
allows for the colonization of new environments while limiting overcrowding in the mature 
biofilm.103-104   The Kjelleberg lab discovered that P. aeruginosa biofilms utilize NO as a chemical 
signal to initiate dispersal upon biofilm maturation.105-107  Biofilms grown with strains of P. 
aeruginosa incapable of NO production (i.e., lacking NIR) did not exhibit coordinated dispersal 
following maturation.105  Furthermore, strains that produced NO but could not scavenge it (i.e., 
lacking NOR) exhibited increased dispersal over wild-type strains.   Exposure to exogenous NO 
released from sodium nitroprusside (SNP) also resulted in biofilm dispersal, indicating that NO-
releasing materials can be used to trigger biofilm dispersal.105  Together, these results demonstrate 
that accumulation of NO within P. aeruginosa biofilms, whether from endogenous or exogenous 
sources, triggers dispersal.  Treatment with exogenous NO also increases the efficacy of co-
administered antibiotics against P. aeruginosa biofilms.  By triggering dispersal and a transition 
to the planktonic state, treatment with NO has been shown to increase bacterial susceptibility to 
traditional antibiotics. 105  For example, pretreatment of biofilms with sub-bactericidal 
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concentrations of SNP (500 mM) increased the bactericidal efficacy of tobramycin by two-logs 
compared to biofilms that were not exposed to SNP.105    
 While biofilm dispersal requires low concentrations of NO (e.g., pM-nM), biofilm 
eradication typically requires higher NO concentrations (e.g., µM).108 Achieving these large local 
NO concentrations requires the use of exogenous NO donors to store and controllably release NO.  
The mechanisms for NO-mediated biofilm toxicity are similar to planktonic bacteria; however, 
higher doses of NO are required for eradication of biofilms due to the protective EPS matrix.  The 
development of NO-releasing materials capable of biofilm eradication will be discussed in more 
detail in Section 1.5. 
1.4 Nitric Oxide in Cystic Fibrosis  
In the lungs and airways, NO controls many regulatory processes, including bronchomotor 
control, inflammation, and the immune response.109  The human airway produces NO from L-
arginine via three isoforms of NO synthase (i.e., nNOS, eNOS, and iNOS).  Bronochomotor control 
is regulated by nNOS in nonadrenergic noncholinergic (NANC) nerves and disruption of nNOS 
activity results in airway obstruction.110  Pulmonary circulation is regulated by eNOS produced in 
the pulmonary blood vessels.  When inhibited, vasoconstriction and vessel wall thickening 
results.111  Finally, macrophages, neutrophils, and bronchial epithelial cells enzymatically produce 
NO via iNOs when stimulated by pro-inflammatory cytokines (i.e., interleukin-1 tumor necrosis 
factor and interferon-gamma) or by lipopolysaccharides secreted by bacteria.112  
1.4.1 Causes of low exhaled NO in CF patients 
In airway diseases associated with inflammation or chronic infections (e.g., asthma and 
COPD), exhaled NO concentrations are increased, especially during exacerbations.  Surprisingly, 
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exhaled NO levels in CF patients are similar to or decreased compared to healthy individuals, 
despite the intense inflammation associated with CF.109  Two main hypotheses are used to explain 
the decreased levels of exhaled NO in patients with CF.  First, many scientists believe that high 
levels of NO are produced in CF airways but that NO cannot be detected in the exhaled breath of 
CF patients because the highly viscous mucus layer prevents NO from reaching the gas phase.109  
In this case, a significant fraction of NO is converted into its stable metabolites (i.e., nitrate, nitrite, 
and nitrotyrosine) in the CF mucus prior to NO measurement.109  In one study, exhaled 
concentrations of NO were similar in CF patients and healthy individuals, but nitrate and 
nitrotyrosine concentrations in sputum were significantly higher in the CF subjects, supporting this 
hypothesis.113  Moreover, no differences in exhaled NO were measured when stable (i.e., non-
exacerbated) CF patients were compared to those with acute respiratory infections while elevated 
nitrate and nitrite concentrations were detected in patients with active infections.114 Finally, it has 
been reported that NO consumption by P. aeruginosa during anaerobic metabolism reduced levels 
of exhaled NO (Figure 1.8).115  Together, these studies suggest that NO production is not 
diminished in the CF airway, but rather that NO is consumed or degraded in CF mucus prior to 
detection in exhaled breath. 
Alternatively, others hypothesize that NO production is indeed curtailed in CF patients.  
Bio-available concentrations of L-arginine, the substrate for NO production by NOS, are decreased 
in CF, resulting in diminished NO production.116-117  The NO production may be reduced due to 
downregulation of iNOS in CF airways.118  In a CF mouse model, total NOS activity was 
downregulated in the trachea of CF mice compared to wild type.118  While NO activity was 
stimulated with LPS and L-arginine in wild-type mice, NO production was not affected in the CF 
model, indicating that iNOS cannot be upregulated during bacterial colonization and infection.118  
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It is believed that the failure to upregulate iNOS during infection is related to the CFTR mutations 
and not chronic infection, as depressed NO levels are seen in infants with CF who have never 
experienced infection or prolonged bouts of inflammation.118 As evidence exists to support both 
views, it is likely that NO production is limited in CF airways and that measurements of exhaled 
NO do not accurately assess NO production. 
1.4.2 Implications of low exhaled NO levels in CF 
Reduced concentrations of exhaled NO have been associated with poor pulmonary health 
in CF patients.109,116,119  Most notably, the loss of iNOS activity decreases the ability of the host 
immune response to prevent infection by bacteria and viruses.  Mice with impaired iNOS 
upregulation were shown to be less able to eradicate P. aeruginosa from the airways than wild-
type mice.118  Limited NO production by iNOS also diminishes the ability to fight viral infection, 
as high levels of NO are also required to inhibit viral replication.120-121   
Decreased NO in the airways also likely affects the chronic hydration of CF airways.  
Soluble guanylate cyclase, which produces cyclic guanosine monophosphate (cGMP), is activated 
by NO.122  As cGMP downregulates amiloride-sensitive sodium absorption, chronically low levels 
of NO may contribute to inhibited cGMP availability and the resulting hyperabsorption of sodium 
in  the CF airways.109,122  While research into the causes and implications of low exhaled NO 
concentrations in CF patients is still ongoing, new therapeutic approaches are being designed to 
supplement NO levels in CF airways. These technologies will be discussed in Section 1.5. 
1.5 Nitric Oxide as a Cystic Fibrosis  Therapeutic 
 To augment NO concentrations in the airways, two main approaches have been 
investigated:   L-arginine supplementation and inhalation of NO gas.  Both approaches are active 
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research areas; however, neither approach is currently FDA approved as a CF therapeutic.   As 
discussed in Section 1.4.1, L-arginine is a substrate for NO production that is found in reduced 
concentrations in the CF airways.  In order to correct this deficiency, L-arginine can be 
supplemented orally, intravenously, or via inhalation.  Both oral and intraveneous administration 
of L-arginine have been shown to increase concentrations of exhaled NO compared to placebo 
treatment in CF and healthy patients,123-124 but no increase in pulmonary function was observed.   
Despite increased exhaled NO concentrations, NO levels in CF patients were still lower than 
untreated healthy controls, indicating that L-arginine supplementation alone does not fully 
compensate for deficiencies in NO production.   
Inhalation of nebulized solutions is more effective than intravenous administration of L-
arginine.  After a single dose of nebulized L-arginine (18 mL of 7% L-arginine hydrochloride 
solution), CF patients exhibited increased exhaled NO concentrations as well as improved 
pulmonary function, as characterized by increased forced air expiratory volume in 1 second (FEV1) 
and improved oxygen saturation.125  In a separate study inhalation of nebulized L-arginine twice 
daily for two weeks improved exhaled NO levels but not FEV1 compared to inhalation of saline 
solution over the same period.126  Together these trials suggest that L-arginine supplementation, 
particularly via inhalation, is a potential therapeutic for increasing exhaled NO concentrations in 
people with CF.  However, currently no evidence exists indicating L-arginine supplementation 
improves pulmonary function over longer periods.  Additionally, L-arginine supplementation will 
never fully restore NO concentrations in CF airways if iNOS is downregulated in CF, as currently 
hypothesized.118 
  While L-arginine supplementation attempts to increase NO concentrations by upregulating 
host NO-production, NO levels can be more easily supplemented by the direct inhalation of NO 
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gas.  As such, several studies have investigated the utility of gaseous NO as a pulmonary 
therapeutic. In adults with COPD, NO gas inhalation has been shown to reduce pulmonary 
hypertension.127  One early study on non-exacerbated CF patients showed no immediate 
improvement in lung function after inhalation of 0.1-40 ppm NO.128 However, inhalation of NO 
gas at higher concentrations or during exacerbations may improve the utility of this therapeutic. 
 Since these early studies, the use of NO gas as a CF therapeutic has changed focus to its 
potential as an antibacterial treatment.  As summarized in Table 1.2, three separate research groups 
have measured decreased bacterial loads in rats infected with P. aeruginosa following inhalation 
of NO gas.   It was first demonstrated that inhalation of NO gas (40 ppm, 24 h) could significantly 
reduce P. aeruginosa colonization in intratracheally injected rats compared to those treated with 
room air.129  As inhalation of 40 ppm for 48 h resulted in death in a sizable minority of rats,129 
lower doses (10 ppm) of NO were investigated next.130   This reduced NO dose was only effective 
at bacterial eradication when balanced with pure oxygen instead of room air, which increased 
airway inflammation.130  In an attempt to approve bactericidal efficacy while reducing toxicity, 
Miller’s group administered higher NO doses (160 ppm) intermittently.131  This regimen resulted 
in similar decreases in bacterial load with the added advantage of preventing inflammation. 
 Based on these studies, it is certain that NO has the potential to be an effective antibacterial 
agent for pulmonary P. aeruginosa infections.   As such, inhaled gaseous NO is being investigated 
as a supplemental treatment to current antibiotic therapies.  In an initial clinical trial, the addition 
of NO inhalation (5-10 ppm for 8 h/day) to intravenous tobramycin or ceftazidime treatment 
reduced the number of biofilm aggregates and improved FEV1 compared to inhaled placebo gas 
in CF patients.132 
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Table 1.2     Inhalation of NO gas to treat P.aeruginosa airway infections in rat models. 
Reference Year 
Corresponding 
Author 
NO Concentration 
P. aeruginosa 
Reduction 
(log10) 
129 2000 Sanjay Mehta 
40 ppm in air 
(continuous administration) 
1.7 
130 2002 Christophe Delclaux 
10 ppm in oxygen 
(continuous administration) 
2 
131 2013 Christopher Miller 
160 ppm in air 
(30 min every 4 h) 
2 
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 These initial studies demonstrate that NO has the potential to become an effective 
therapeutic for reducing bacterial infections and improving pulmonary function in patients with 
CF.  While these studies are important proofs of concept, the potential utility of inhaled NO gas is 
limited by convenience, patient compliance, and toxicity concerns.  The clinical trial described 
above required patients to be connected to a pressurized NO gas tank for 8 hours a day, a treatment 
that is impractical for young or active patients.  Inhalation of NO gas is also costly ($125/h or 
$1000/d) for chronic treatment.82,133  As such, new research into the development of NO-releasing 
materials that can more conveniently deliver NO to the airways are being developed.  These 
materials will be discussed in Section 1.6. 
1.6 Nitric Oxide-Releasing Materials as Potential Cystic Fibrosis Therapeutics 
 While NO holds promise as a potential CF therapeutic, materials must be developed to 
effectively store and controllably release NO over an extended period of time as the expense, 
inconvenience, and potential toxicity associated with NO gas inhalation limit its clinical utility.  
Macromolecular scaffolds designed to store and release NO are generally more effective at 
eradicating bacteria than gaseous NO or low-molecular weight donors.78,81,134-135  By allowing for 
localized delivery, the minimum NO-dose required for bacterial eradication can be reduced, thus 
improving the safety of NO therapy.  Additionally, inhalation of NO-releasing materials is a more 
convenient therapeutic strategy than inhalation of gaseous NO.  As NO can be released from 
macromolecular scaffolds for several hours, continuous NO delivery to the airways can be 
achieved by intermittent treatment rather than continuous inhalation from a pressurized gas 
cylinder. 
Many NO-releasing materials have been developed for a range of medical applications. 
However, most scaffolds are unsuitable for pulmonary delivery. Silica nanoparticles81,88-89,93,136 
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and dendrimers90,95,98-99,137-138 have been developed as effective NO-release vehicles for 
dermatological and dental applications, but toxicity concerns and ineffective clearance from the 
lungs make these scaffolds unsuitable for inhalation.  Acidified nitrite and NO-releasing chitosan 
oligosaccharides are currently the primary NO-releasing materials being evaluated as potential 
inhalable therapeutics.    
1.6.1 Acidified nitrite 
 Under acidic conditions (i.e., pH < 6.5), nitrite (NO2
-) is converted to nitrous acid (HNO2) 
and can be used as non-enzymatic NO source.139-140  This release strategy has been used to prevent 
infections in cutaneous wounds via the co-application of creams containing acetic acid and sodium 
nitrite (NaNO2).
82,141-144   In CF, sodium nitrite can be inhaled directly and protonated in the acidic 
environment of the CF mucus layer to form HNO2.
145-146   Generation of NO from 15 mM NaNO2 
at pH 6.5 (the reported pH of CF mucus) has been measured electrochemically in bacterial growth 
medium to yield a NO formation rate of 4 µM/h with a maximum NO concentration of 500 nM.145  
These results confirm that NO can be generated from NaNO2 under CF-mimicking in vitro 
conditions.  
 As a potential CF therapeutic, acidified nitrite has been investigated as a broad-spectrum 
antibacterial agent, particularly for the eradication of bacteria in hypoxic or anaerobic 
environments typical of CF mucus.   Yoon et al.145 determined that sodium nitrite could eradicate 
P. aeruginosa only when culture conditions were below pH 7, indicating that the acidification of 
nitrite was required for antibacterial activity.  At this pH, the ability of acidified nitrite to eradicate 
mucoid P. aeruginosa was demonstrated for clinical strains, anaerobically grown biofilms, and in 
a mouse model.145  Of particular relevance to CF, mucoid P. aeruginosa showed increased 
susceptibility to acidified nitrite compared to nonmucoid strains.  This increased vulnerability is 
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likely caused by the substantially lower NOR activity (required for NO detoxification during 
anaerobic respiration) of mucoid P. aeruginosa compared to the nonmucoid phenotype.145  Growth 
of S. aureus, MRSA, and several B. cepacia strains was also inhibited by 15 mM sodium nitrite at 
pH 6.5, and biofilm viabilities of these strains were reduced by 1–2 logs after two days of 
treatment.146  As with P. aeruginosa, the toxicity of acidified nitrite to S. aureus and B. cepacia 
was attributed to its conversion to acidified nitrite and subsequent reduction to NO.  
 Despite the published antibacterial efficacy of sodium nitrite, the control of NO generation 
poses a significant challenge.   The dosage of NO is dependent upon the concentration of NO2
- 
inhaled and the pH of the airway, which has been reported to range from 6.39 ± 0.04145 to 7.1 ± 
0.2.147  As such, the rate of NO generation from sodium nitrite cannot be controlled.  It has 
previously been demonstrated that the kinetics of NO generation or release are important for the 
effective eradication of bacteria and biofilms.78,88-89,96,135  Therefore, controllable NO release from 
macromolecular scaffolds represents the next generation of NO-based therapeutics for the 
treatment of CF. 
1.6.2 Nitric oxide-releasing chitosan oligosaccharides 
Chitosan is a naturally derived polymer comprised of repeating units of N-
acetylglucosamine and D-glucosamine (Figure 1.9).  The molecular weight of chitosan depends on 
the chitin from which it is derived and generally ranges from 20 kD to 375 kD.148  Chitosan is 
easily broken down to smaller units via oxidative or enzymatic degradation.149-150  The degree of 
deacetylation (i.e., the percentage of D-glucosamine monomers) ranges from 0 (chitin) to 100% 
and determines the number of primary amines available per linear polymer chain.  Both the 
molecular weight and deacetylation degree affect the solubility, toxicity, and mucoadhesion of the 
polymer.    
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Figure 1.9 Chemical structure of chitosan.  Chitosan is comprised of repeating units of N-
acetylglucosamine and D-glucosamine monomers. 
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 Mucoadhesion is an important property in pulmonary drug delivery as it has been 
correlated with increased drug retention times.151  As reported by Yamamoto et al., poly lactic-co-
glycolic acid (PLGA) copolymer nanospheres loaded with calcitonin were more slowly eliminated 
from the lungs of guinea pigs when modified with chitosan, allowing for sustained drug release.152  
The mucoadhesive properties of chitosan are related to its polycationic nature, as primary amines 
on chitosan interact with the negatively charged sialic acid residues of mucins.153-154  Highly 
deacetylated chitosan is thus more mucoadhesive than chitosan polymers with a low degree of 
deacetylation.154  In addition to electrostatic attractions, hydrogen bonding and hydrophobic 
interactions contribute to chitosan mucoadhesion.154 
 As with all drug delivery systems, pulmonary excipients must be nontoxic.  Based on its 
low toxicity, chitosan has been approved for dietary applications in Japan, Italy, and Finland,155 
and for use in wound dressings in the United States.156  While chitosan is generally considered 
nontoxic, the degree of deacetylation may alter the inherent toxicity of chitosan scaffolds.  In two 
different studies, it was found that exposure to highly deacetylated chitosan (~80% deacetylation) 
was significantly more toxic to human lung epithelial cells than exposure to chitosan with lower 
degrees of deacetylation (~40%).151,157  In addition to having more primary amines, highly 
deacetylated chitosan polymers have extended conformations due to intramolecular electrostatic 
repulsion, which further increase their ability to bind to cell membranes.156 
The biodegradability of chitosan sets it apart from many other NO delivery scaffolds and 
makes it particularly suitable for pulmonary deliver in stagnant CF mucus.  Polymeric chitosan 
with molecular weights less than 30 kD are cleared by the liver.  In contrast, chitosan polymers 
larger than 30 kD need to be enzymatically degraded by lysozyme in vivo prior to elimination.148   
Lysozyme is secreted in the airways at 10-20 mg/day, making biodegradation of chitosan in the 
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lungs possible;158 however, systematic studies on the biodegradation and clearance of chitosan 
from the airways are lacking.  
  The low toxicity, mucoadhesive properties, and biodegradability of chitosan make it 
suitable for the development of an inhalable, NO-releasing scaffold.  Chitosan is only soluble in 
acidic aqueous solutions (pH < 6.5), limiting the number of delivery mechanisms available.  To 
make chitosan suitable for use with dry powder inhalers, it has been formulated into drug-releasing 
macroparticles (1–3 µm).151,155  Upon degradation of these macroparticles, large chitosan polymers 
are deposited in the airways and require further degradation by enzymes.  To solve both the 
solubility and degradation problems associated with chitosan polymers, chitosan may be 
exogenously degraded into oligosaccharides prior to therapeutic use.  Chitosan oligosaccharides 
are low molecular weight (i.e., less than 10 kD).  In vitro degradation to oligosaccharides improves 
the solubility of chitosan in water, making it possible for delivery to the airways via 
nebulization.150  As dehydration of the ASL is a symptom of CF, nebulization provides an 
advantage over dry powder inhalers because it hydrates the ASL during drug delivery.  Due to 
these inherent advantages, we have pursued the use of chitosan oligosaccharides as an alternative 
to polymeric chitosan for the development of inhalable NO-releasing scaffolds. 
The formation of S-nitrosothiol or N-diazeniumdiolate NO donors on the scaffold is readily 
achieved to impart NO storage and release capabilities to the chitosan oligosaccharides.  As shown 
in Figure 1.10, S-nitrosothiols (RSNOs) are NO donors that are formed by the reaction of 
sulfhydryl groups with a nitrosating agent (e.g. alkyl nitrite, dinitrogen trioxide, nitrous acid).159   
Release of NO from RSNOs is triggered by heat, light, copper, or ascorbic acid (Figure 1.10).134,159  
In the airways, NO release from RSNOs may occur through thermal cleavage of the S-N bond to 
generate NO and a thiyl radical.  While reaction with ascorbic acid may generate NO in vivo,  
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Figure 1.10 Reactions for the formation and decomposition of S-nitrosothiols.  In the 
airways, the thermal decomposition pathway is predominant. 
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ascorbic acid depletion is a known characteristic of the ASL in CF patients.160  
Lu et. al. previously reported the synthesis, NO-release characteristics, and antibacterial 
activity of RSNO-modified chitosan oligosaccharides.161  Thiolation of the chitosan 
oligosaccharide scaffold was achieved with 2-iminothiolane hydrochloride and 3-acetamido-4,4-
dimethylthietan-2-one to form chitosan-TBA and chitosan-NAP, respectively.  Both thiolated 
chitosan oligosaccharides were nitrosated with acidified nitrite to form RSNOs.   Under release 
conditions simulating that which is likely in the airways (i.e., 37 °C, without ascorbic acid or light), 
chitosan-TBA-NO and chitosan-NAP-NO liberated low levels of NO (35 ± 5 and 240 ± 40 nmol 
NO/mg chitosan, respectively).  Due to such low NO payloads, the concentration of chitosan-TBA-
NO and chitosan-NAP-NO required to eradicate planktonic cultures of P. aeruginosa were 
significant (15 and 30 mg/mL, respectively).  N-diazeniumdiolate-modified chitosan 
oligosaccharides may represent a more suitable NO-release system for overcoming the low 
bactericidal action of RSNO modified chitosan oliogosaccharides.97 
The N-diazeniumdiolate NO donor is formed by exposure of amines to high pressures of 
NO gas, typically under basic conditions.134  The most widely accepted mechanism of N-
diazeniumdiolate NO-donor formation is shown in Figure 1.11-A, in which NO dimerizes to N2O2 
at elevated pressures and subsequently reacts with a secondary amine to form an N-
diazeniumdiolate.162  While N-diazeniumdiolates may form on primary amines, these NO donors 
are highly unstable and therefore not suitable for extended release.137  In physiological 
environments, N-diazeniumdiolates decompose to release two equivalents of NO (Figure 1.11-B).  
The NO-release kinetics in aqueous solutions are controlled by pH, temperature, and the 
hydrophobicity of the scaffold surrounding the N-diazeniumdiolate.97,134 
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Figure 1.11 The (A) formation and (B) decomposition of N-diazeniumdiolates. 
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Utilizing the N-diazeniumdiolate moiety to impart NO storage and release to chitosan 
oligosaccharides, Lu et al. reported increased NO payloads and bactericidal efficacy compared to 
RSNO-modified counterparts.97 To form the most stable N-diazeniumdiolates, existing primary 
amines on native chitosan oligosaccharide scaffolds were modified with 2-methylaziridine to yield 
secondary amines (Figure 1.12).  The 2-methylaziridine-modified chitosan oligosaccharides were 
then exposed to high pressures of NO under basic conditions to yield N-diazeniumdiolate-modified 
chitosan oligosaccharides (Figure 1.12).  These NO-donor scaffolds were capable of releasing NO 
payloads approaching 1 µmol NO/mg chitosan, and having improved bactericidal action.  Only 
0.2 mg/mL of N-diazeniumdiolate-modified chitosan oligosaccharides were required to eradicate 
planktonic bacteria, a > 99% decrease from the RSNO-modified chitosan oligosaccharides.161   The 
improved bactericidal efficacy was attributed to both the increased NO payloads and the highly 
cationic nature of the 2-methylaziridine modified chitosan oligosaccharide scaffold.  As cationic 
scaffolds likely associate with the negatively charged bacteria membrane to a greater extent than 
neutral or negatively charged scaffolds,163-164  the pendant amine on the 2-methlyaziridine 
modification enhances localized delivery of NO.   Indeed, the antibacterial efficacy of the N-
diazeniumdiolate modified chitosan oligosaccharides was great enough to eradicate P. aeruginosa 
biofilms at concentrations found to be non-toxic to mammalian cells.97  
In summary, the low toxicity, mucoadhesive properties, and biodegradability of chitosan 
make it a suitable scaffold for pulmonary NO delivery.  By degrading the chitosan polymer to 
oligosaccharides (<10 kD), water solubility is achieved, allowing for future nebulization.  When 
modified with N-diazeniumdiolate NO donors, chitosan oligosaccharide scaffolds were capable of 
controlled NO release and eradication of P. aeruginosa biofilms at concentrations non-toxic to 
mammalian cells.97  These materials hold great potential as alternatives to inhalation of NO gas  
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Figure 1.12 Synthesis of N-diazeniumdiolate modified chitosan oligosaccharides. 
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delivered from pressurized cylinders or the use of acidified nitrite because the mucoadhesion, NO 
payload, and release kinetics are all easily modified synthetically to maximize delivery and killing 
action.  Of importance, the ability to eradicate mucoid P. aeruginosa in reduced oxygen 
environments needs remains unknown.  Additionally, biophysical investigation of the effects of 
NO and NO-releasing chitosan oligosaccharides on CF biofilms and mucus are lacking.  These 
important properties must be determined before NO-releasing chitosan oligosaccharides may be 
advanced a therapeutic for CF. 
1.7 Summary of Dissertation Research 
The goal of my dissertation research was to evaluate NO-releasing chitosan 
oligosaccharides in their capacity as potential CF therapeutics.  As such, my thesis work focused 
on the antibacterial efficacy of NO in CF-relevant conditions, and determining its effects on the 
physical properties of CF ASL components (i.e., bacterial biofilms and mucus).  The following 
specific aims represent the goals of my work: 
1) Determining the antibacterial efficacy of NO-releasing chitosan oligosaccharides against 
relevant P. aeruginosa strains under culture conditions which accurately mimic CF 
airways; 
2) Quantifying the effects of NO-releasing and non-NO-releasing chitosan oligosaccharides 
on the biophysical properties of P. aeruginosa biofilms; and,  
3) Evaluating the ability of NO-releasing chitosan oligosaccharides to reduce mucin 
molecular weight and the rheological properties of CF sputum. 
 
In this chapter, CF pathogenesis was introduced as a function of the biophysical properties of 
the airways.  As defective chloride ion transport decreases ASL hydration, the resulting 
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accumulation of highly viscous mucus promotes bacterial infection and subsequent lung 
degradation.  Motivation was also provided for the development of NO-based therapies for the 
treatment of CF.  Inhalation of NO gas has proven effective in small animal studies and is safe for 
healthy adults.  However, the inconvenience and high cost of gaseous administration warrants the 
development of new delivery mechanisms.  To this end, NO-releasing chitosan oligosaccharides 
have been proposed as a potential CF therapeutic.  As these materials are water soluble and exhibit 
prolonged NO release, inhalation of NO-releasing materials via nebulization would allow for 
prolonged NO delivery to the airways.  In Chapter 2, I will describe the use of NO-releasing 
chitosan oligosaccharides for determining the antibacterial efficacy of NO against P. aeruginosa 
under CF-relevant conditions.  In these studies, alterations in the antibacterial activity of NO as a 
function of bacteria metabolism, phenotype, and oxygen availability were investigated.  Chapter 3 
details the effects of NO-releasing chitosan oligosaccharides and tobramycin treatment on the 
viscoelasticity of P. aeruginosa biofilms as determined via multiple particle tracking 
microrheology.  Chapter 4, describes the synthesis of NO-releasing chitosan oligosaccharides with 
different modifications to create materials with a range of mucoadhesive strengths.  Furthermore, 
the use of these materials to examine how the mucoadhesion of the scaffold alters the ability of 
NO to degrade mucins from human bronchial epithelial cell cultures and clinical samples of CF 
sputum are detailed.  Lastly, Chapter 5 provides a summary of my dissertation work and suggests 
future directions for the evaluation of NO-release scaffolds for the treatment of CF.  
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CHAPTER 2: ANTIBACTERIAL ACTION OF NITRIC OXIDE-RELEASING CHITOSAN 
OLIGOSACCHARIDES AGAINST PSEUDOMONAS AERUGINOSA IN CYSTIC 
FIBROSIS-RELEVANT CONDITION 
2.1 Introduction 
Cystic fibrosis (CF) is a genetic autosomal recessive disorder that affects > 70,000 people 
worldwide.1  Genetic mutations in the transmembrane conductance regulator (CFTR) gene disrupt 
the movement of water and ions across the airway surface, resulting in a dehydrated, highly viscous 
mucus layer.  In addition to preventing mucociliary clearance (i.e., the main mechanism of the 
airways to prevent bacterial infection), this mucus layer also provides an ideal environment for 
bacterial biofilm formation.2-3  Disease and degradation of the lungs caused by such biofilms 
represent the leading causes of morbidity and mortality in CF patients.4 As more than 80% of 
adults with CF suffer from chronic Pseudomonas aeruginosa (P. aeruginosa) infections, the 
development of an effective treatment capable of efficient biofilm eradication would dramatically 
improve their life span.5 
Several interrelated factors contribute to the poor efficacy of current antibiotics against P. 
aeruginosa in CF airways.  Chronic CF infections are characterized predominately by the mucoid 
phenotype, resulting in increased alginate production.6  Alginate encapsulates bacteria, providing 
a physical barrier against the host immune system and antibiotics.7   Increased neutrophil activity 
in CF mucus also lowers oxygen levels and increases nitrate concentrations in the airways.8-9  
Consequently, bacteria metabolism occurs through anaerobic respiration via denitrification. This 
process is inefficient compared to aerobic respiration and ultimately slows bacterial growth. The 
reduced metabolic activity of P. aeruginosa in anaerobic CF mucus protects the bacteria against 
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traditional antibiotics that are most effective against rapidly dividing cells, including 
aminoglycosides and β-lactams.9-10 
The failure of conventional antibiotics to treat P. aeruginosa infections in CF airways 
necessitates the development of new antibacterial agents.  Nitric oxide (NO), an endogenously 
produced free radical that can disperse11-12 and eradicate13-14 biofilms, holds particular promise as 
a CF treatment.  In aerobic environments, NO reacts with molecular oxygen, superoxide, and 
hydrogen peroxide to form highly reactive intermediates (peroxynitrite, nitrogen dioxide, and 
dinitrogen trioxide).  These molecules cause DNA deamination, nitrosation of membrane and 
intracellular proteins, and membrane damage via lipid peroxidation through both nitrosative and 
oxidative stresses, culminating in bacteria death.15-18  Some of these congener molecules, 
especially peroxynitrite, are more potent antimicrobials than NO alone.16  In anaerobic 
environments such as CF mucus, NO toxicity is less understood.  Ren et al. reported the 
bacteriostatic mechanisms to include modification of iron-sulfur proteins.19  As these proteins are 
linked to nearly every cellular process including metabolism, respiration, RNA modification, and 
DNA repair and replication, their alteration greatly influences bacteria viability.20 
Diminished airway and exhaled NO are characteristic for patients with CF, possibly correlating 
to greater susceptibility to infection.21-22  While the administration of exogenous NO holds promise 
as a therapeutic, direct inhalation of gaseous NO is highly impractical and dangerous as NO 
mediates other physiological processes (e.g., vasodilation and blood clotting).23-24  
Macromolecular scaffolds capable of effectively storing and releasing NO have been developed to 
enable local delivery.25-26  The most promising NO-release vehicles to date include NO donor-
modified  N-diazeniumdiolate silica nanoparticles,27-29 dendrimers,30-34 and chitosan.14   While 
silica nanoparticles13,35-37 and dendrimers30-32 are effective as antimicrobials, they do not easily 
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break down and thus have limited potential as inhaled therapeutics.  Chitosan-based 
oligosaccharides represent attractive scaffolds for pulmonary NO delivery as they are 
biodegradable and of low toxicity to mammalian cells.38-39  We have previously reported that NO-
releasing chitosan oligosaccharides are capable of NO storage/release and eradicating P. 
aeruginosa biofilms under aerobic environments at concentrations non-toxic to mammalian 
cells.14  Herein, we evaluate the antibacterial efficacy of NO-releasing chitosan oligosaccharides 
using P. aeruginosa phenotypes (i.e., nonmucoid, mucoid, and biofilm) and oxygen concentrations 
that mimic those of the CF airway to more fully elucidate the potential of these materials as CF 
therapeutics. 
2.2 Materials and Methods 
2.2.1 Materials 
 Medium molecular weight chitosan, 2-methylaziridine, and tobramycin were purchased 
from Sigma-Aldrich (St. Louis, MO). Methyltrimethoxysilane (MTMOS) was purchased from 
Fluka (Buchs, Switzerland). (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17 
FTMS) was purchased from Gelest (Morrisville, PA).  Nitric oxide gas was purchased from Praxair 
(Sanford, NC).  Standardized NO gas (26.85 ppm, balance N2), Argon (Ar), and nitrogen (N2) 
gases were purchased from Airgas National Welders (Durham, NC).  Sodium methoxide was 
purchased from Acros Organics (Geel, Belgium).  Distilled water was purified using a Millipore 
Milli-Q UV Gradient A-10 system (Bedford, MA).  All common laboratory salts and reagents 
were purchased from Fisher Scientific (Pittsburgh, PA).  All materials were used without further 
purification unless otherwise specified.    
2.2.2 Bacteria strains and media   
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The laboratory P. aeruginosa strain used in this study was strain K (PAK).  The nonmucoid 
phenotype and mucoid phenotype (mucA22) were a gift from Prof. Matthew Wolfgang, UNC 
Department of Microbiology and Immunology (Chapel Hill, NC).  Clinical isolates were collected 
from patients at the UNC Hospital Clinical Microbiology Lab (Chapel Hill, NC).  Clinical isolates 
were screened for tobramycin resistance using the Kirby Bauer disk diffusion method according 
to standards published by the Clinical and Laboratory Standards Institute in document M100-
S23.40  All bacteria were grown in Luria Bertani (LB) broth (BD Biosciences, San Jose, CA) with 
the pH adjusted to 6.5 using 10 mM sodium phosphate.  When indicated, potassium nitrate (15 
mM) was added to the broth. Phosphate buffered saline (PBS) was adjusted to pH 6.5 with 10 mM 
sodium phosphate.  Anaerobic media was kept in a Coy anaerobic chamber (Coy Laboratory 
Products, Ann Arbor, MI) with the lid loosened for one week prior to use. 
2.2.3 Synthesis of 2-methylaziridine modified chitosan oligosaccharides 
2-Methylaziridine modified chitosan oligosaccharides were synthesized as previously 
published.14  Briefly, medium molecular weight chitosan (2.5 g) was oxidatively degraded to ~5 
kD in 15% hydrogen peroxide for 1 h at 85 °C.  Non-degraded chitosan was removed by filtration.  
The remaining chitosan oligosaccharides were precipitated from solution with acetone, collected 
via centrifugation, and dried in vacuo.  The ~5 kD chitosan oligosaccharides (500 mg) were then 
dissolved in water (10 mL). Concentrated hydrochloric acid (27.6 µL), water (250 µL), and 2-
methylaziridine (356 µL) were then added to this solution.  The reaction was stirred for 5 d at 25 
°C followed by 24 h at 75 °C.  The modified chitosan oligosaccharides were again precipitated 
with acetone, collected via centrifugation, and dried in vacuo.  1H NMR data of COS: (400 MHz, 
D2O, δ): 0.8–1.1 (NH2CH(CH3)CH2NH), 1.9 (C7: CHNHCOCH3), 2.3–2.9 
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(NH2CH(CH3)CH2NHCH, C2: NH2CH(CH3)CH2NHCH), 3.3–4.0 (C3, C4, C5, C6: OHCH, 
OCHCH(OH)CH(NH2)CH, OHCH2CH, OHCH2CH), 4.4 (C1: OCH(CHNH2)O). 
2.2.4 Synthesis of NO-releasing chitosan oligosaccharides 
In order to impart NO storage and release, N-diazeniumdiolates were formed on the 
secondary amines of COS.14  Briefly, COS (15 mg) was dissolved in a solution of water (300 µL), 
methanol (700 µL) and 5.4 M sodium methoxide (25 µL) in a 1 dram vial equipped with a stir bar.  
The open vial was placed in a 160 mL Parr general purpose stainless steel pressure vessel and 
rigorously stirred.  Oxygen was removed from the reaction vessel by purging with argon (10 s, 8 
bar) 3 times, followed by 3 additional long argon purges (10 min, 8 bar).  The vessel was then 
filled with potassium hydroxide-purified NO gas (10 bar) for 72 h at room temperature.  
Afterwards, the argon purging procedure was repeated to remove unreacted NO.  The N-
diazeniumdolate-modified chitosan oligosaccharides (COS-NO) were precipitated in acetone, 
collected via centrifugation, dried in vacuo, and stored at -20 °C as a yellow powder. 
2.2.5 Chemiluminescence detection of NO 
A Sievers 280i Chemiluminescence Nitric Oxide Analyzer (Boulder, Colorado) was used 
for chemiluminescence detection of NO from COS-NO (1.0 mg) in 30 mL of deoxygenated PBS 
(pH 6.5) at 37 °C. Released NO was carried by N2 gas to the reaction vessel/detector at a flow rate 
of 80 mL/min.  Additional N2 flow was supplied to the sample flask at 200 mL/min to match the 
collection rate of the instrument.  The analysis was terminated when NO concentrations fell below 
10 ppb NO/mg COS-NO.  Prior to analysis, the instrument was calibrated with air passed through 
a NO zero filter (0 ppm NO) and 26.8 ppm of NO standard gas (balance N2). 
2.2.6 Electrochemical detection of NO 
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Home built NO-selective electrochemical sensors were fabricated as previously reported.41  
Briefly, polished polycrystalline Pt disk electrodes (2mm) sealed in Kel-F (CH Instruments, 
Austin, TX) were coated with a NO-selective xerogel membrane prepared by mixing MTMOS (60 
µL), ethanol (300 µL), 17 FTMS (15 µL), water (80 µL), and 0.5 M hydrochloric acid (5 µL) for 
1 h at 25°C. The resulting sol was spreadcast over the Pt electrode and dried overnight at room 
temperature.   Amperometric NO measurements followed using a three-electrode set up with the 
NO-selective membrane-modified Pt electrode as the working electrode, a Pt-coiled counter 
electrode, and a Ag/AgCl reference electrode.  The applied potential for NO oxidation was +700 
mV vs. Ag/AgCl.  Immediately prior to use, NO sensors were calibrated by adding a known 
amount of PBS saturated with NO gas (1.9 mM) into deoxygenated PBS (pH 6.5). Saturated NO 
solutions were made on the day of use by degassing PBS (pH 6.5) for 30 min with Ar followed by 
20 min purging with NO gas. The sensors were immersed in 10.0 mL of PBS or LB broth (stirred, 
37 °C), and polarized at +700 mV vs. Ag/AgCl until a stable baseline was achieved prior to the 
addition of COS-NO. The NO oxidation current was measured every 0.1 s and ceased when the 
current returned to its background value.  Measurement of NO release in anaerobic media was 
carried out in a Coy Anaerobic Chamber.  Total NO for 1.0 mg COS-NO/mL solutions are reported 
as the average ± the standard deviation for 4 or more separate measurements. 
2.2.7 Planktonic bactericidal assays   
Bacteria were grown as overnight cultures, diluted 1:100 in fresh LB broth (with or without 
nitrate supplementation), and grown to mid-log phase (2×108 CFU/mL).  These cultures were 
centrifuged, resuspended in PBS, and diluted to 2×106 CFU/mL in PBS.  Each suspension was 
then added to vials containing COS-NO or COS-controls, and incubated at 37°C for 4 h with gentle 
shaking.  Following treatment, bacteria solutions were serially diluted, spiral plated on LB Agar, 
67 
 
and incubated for 24 h at 37°C.  Colonies were enumerated using a Flash & Go colony counter 
(IUL, Farmingdale, NY). The minimum bactericidal concentration (MBC4h) was defined as the 
minimum concentration required to achieve a 3-log reduction in viable bacteria (from 106 to 103 
CFU/mL).  The plating counting method employed has a limit of detection of 2.5 x103 CFU/mL.42 
2.2.8 Planktonic inhibition assays  
Bacteria were grown as overnight cultures, diluted 1:100 in fresh LB broth, grown to mid-
log phase (2×108 CFU/mL), and diluted to 2×106 CFU/mL in LB.  Bacteria cultures were then 
added to vials containing COS-NO or COS controls, and incubated at 37 °C for 18 h with gentle 
shaking.  The minimum inhibitory concentration (MIC) was determined to be the minimum 
concentration that inhibited visible growth, defined as an optical density < 0.1 at 600 nm. Nitrate-
supplemented LB was used for all stages of bacteria growth and exposure.  Anaerobic experiments 
were performed in a Coy anaerobic chamber. 
2.2.9 Biofilm eradication assays 
Bacteria were grown as overnight cultures, diluted 1:100 in fresh LB broth, and grown to 
mid-log phase (2×108 CFU/mL).  Bacteria cultures were then diluted to 106 CFU/mL in diluted 
(25%) LB Broth supplemented with 15 mM KNO3 (pH 6.5), and grown for 72 h at 37 °C with 
gentle shaking.  The viscous microcolony biofilms formed were easily separated from the growth 
media via pipetting.   The biofilms were harvested by placing a pipette tip near the center of the 
biofilm and applying suction.  The biofilms were then washed by injection into PBS and extracted 
using the same pipetting procedure to remove planktonic or loosely-associated bacteria.  The 
freshly washed biofilms (250 µL) were combined with 750 µL of PBS (pH 6.5), added to vials 
containing COS, COS-NO or tobramycin, and incubated with gentle shaking for 18 h at 37 °C.  
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After treatment, biofilms were washed via pipetting in PBS to remove excess antibacterial agent, 
transferred to 750 µL of PBS (pH 6.5), and gently sonicated to disrupt the biofilm matrix.  
Dispersed biofilms were vortexed, serially diluted, plated, and enumerated on LB Agar.  The 
minimum biofilm eradication concentration (MBEC18h) was defined as the concentration which 
caused a 5-log reduction in viable bacteria (i.e., 108 to 103 CFU/mL) after the 18 h treatment. 
2.2.10 Statistical analysis 
All data are expressed as the mean ± one standard deviation and were analyzed for 
significance (p < 0.05) with a two-tailed Student’s t-test. 
2.3 Results 
2.3.1 Nitric oxide release from COS-NO in media 
Nitric oxide release from COS-NO was measured in deoxygenated PBS (pH 6.5) at 37 °C to yield 
total NO release payloads of 0.86 ± 0.05 µmol NO/mg with an overall release duration 10.2 ± 2.7 
h (Figure 2.1, Table 2.1).  While NO release from macromolecular scaffolds are generally 
measured in deoxygenated media, measuring the amount of bioavailable (i.e., non-scavenged) NO 
is critical for elucidating the biocidal dose-response relationship of NO under intended conditions 
as NO is rapidly scavenged by oxygen and proteins in biological media 43.  Unfortunately, foaming 
associated with nutrient rich media makes chemiluminescence detection difficult and 
irreproducible.41  Thus, we turned to amperometric NO detection to carry out NO measurements 
in broth (LB). 
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Figure 2.1 Chemiluminescence detection of NO release from COS-NO.  The NO release 
from 1.0 mg of COS-NO was determined in deoxygenated PBS (pH 6.5) for comparison with 
other NO-releasing systems.  (A) The NO total and (B) NO flux of representative 
measurements. 
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Table 2.1     Nitric oxide-release properties of COS-NO in PBS (pH 6.5, 37 °C) as determined by 
chemiluminescence detection.   Values are presented as means ± standard deviations for n=3 pooled 
experiments. 
NO Total 
(µmol NO/mg COS-NO) 
Duration 
(h) 
Half-Life 
(h) 
Max Flux 
(PPB/mg) 
0.86 ± 0.05 10.2 ± 2.7 0.63 ± 0.09 3100 ± 800 
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In the absence of NO scavenging (i.e., in deoxygenated PBS), amperometric measurements 
revealed a total NO payload of 0.34 ± 0.17 µmol/mL from the 1.0 mg/mL solution of COS-NO 
over 4 h (Figure 2.2).  As might be expected, both the total NO payload and release duration of 
COS-NO measured via amperometry were reduced compared to chemiluminescence detection.  
These decreases are common for electrochemical sensors that are based on the diffusion of NO to 
the working electrode and the inherent loss of NO to the ambient atmosphere.41   
Under aerobic conditions, oxygen scavenging reduced the amount of free NO available in 
PBS by approximately 35% (0.22 ± 0.08 µmol NO/mL).  Nutrient broth (LB) further diminished 
the available NO payload via scavenging of the NO by proteins in the broth.  The amount of NO 
available in anaerobic LB Broth was reduced to 0.14 ± 0.08 µmol NO/mL, a 66% reduction relative 
to anaerobic PBS. Further reductions (0.027 ± 0.017 µmol/mL) were observed in aerobic LB broth 
due to reaction of NO with oxygen.  
2.3.2 Bactericidal action of the COS scaffold 
To confirm NO was responsible for the observed bacteria killing and not the scaffold, all 
bacteria assays were performed using NO-releasing and control (i.e., non-NO-releasing) chitosan 
oligosaccharides.  In MBC4h assays of planktonic cells, COS did not influence bacteria viability at 
1x or 10x the MBC4h of COS-NO, indicating that the chitosan oligosaccharide alone was not 
bactericidal (Figure 2.3).  Similarly, bacteria viability was not reduced upon treatment of the 
biofilms with 4.0 mg COS/mL (1x MBEC18h) for 18 h under both aerobic and anaerobic conditions 
(Figure 2.4).  With this data, the bactericidal activity of COS-NO is attributed solely to the effects 
of NO and not to toxicity of the COS scaffold.  
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Figure 2.2 Electrochemical measurements of available NO in media. (A) Representative 
NO-release profiles for 1.0 mg/mL of COS-NO in anaerobic PBS, aerobic PBS, anaerobic LB 
broth, and aerobic LB Broth are shown. These values were integrated to find the (B) total 
concentration of available NO in a 1.0 mg/mL solution of COS-NO in biological media over 4 
h. 
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Figure 2.3     Planktonic bacteria viability (in CFU/mL) after a 4 h exposure to COS in PBS.  
Bacteria were grown (A) aerobically and (B) anaerobically in LB (with nitrate 
supplementation) and exposed to COS in PBS (pH 6.5).  
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Figure 2.4     Biofilm viability (in CFU/mL) after exposure to COS.  Bacteria biofilms were 
grown for 72 h, then exposed to COS under aerobic or anaerobic conditions for 18 h.   
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2.3.3 Effect of oxygen on bactericidal action of NO against planktonic P. aeruginosa 
The biocidal action of NO was evaluated with respect to oxygen concentration in the 
treatment media by exposing planktonic cultures to COS-NO in both aerobic and anaerobic PBS 
(pH 6.5) (Table 2.2).  While the same concentration of COS-NO was required to kill both bacteria 
phenotypes under aerobic and anaerobic exposure conditions, the NO dose delivered in anaerobic 
PBS was slightly greater due to reduced NO reaction with oxygen.  For example, the bactericidal 
NO dose for nonmucoid P. aeruginosa was 0.022 ± 0.008 μmol NO/mL under aerobic conditions 
versus 0.034 ± 0.017 μmol NO/mL in deoxygenated (anaerobic) media.  Differences in NO-
payloads between aerobic and anaerobic environments were not statistically significant. 
Bacteria cultures were also grown aerobically and anaerobically to determine if oxygen in 
the growth media affected P. aeruginosa susceptibility to NO.  As anaerobic growth requires 
nitrate, all assays were carried out using nitrate-supplemented LB to enable direct comparison.  
The absence of oxygen in the growth media had no effect on the susceptibility of nonmucoid P. 
aeruginosa to NO.  However, strict anaerobic growth of mucoid P. aeruginosa increased the 
tolerance of this strain to NO by 2-fold (MBC4h of 0.044 ± 0.016 and 0.022 ± 0.008 µmol NO/mL 
for anaerobic and aerobic growth conditions, respectively) (Table 2.2).  The increased tolerance to 
NO was observed under both aerobic and anaerobic exposure conditions.  
2.3.4 Inhibition of planktonic P. aeruginosa growth by COS-NO 
Minimum inhibitory concentration (MIC) assays were performed to evaluate the efficacy 
of COS-NO during bacterial growth under aerobic and anaerobic environments (Table 2.3).  Under 
aerobic conditions, the nonmucoid phenotype was more tolerant to COS-NO than the mucoid 
strain with inhibitory doses of 800 µg COS-NO/mL (0.022 ± 0.014 µmol NO/mL) versus 400 µg 
COS-NO/mL (0.011 ± 0.007 µmol NO/mL), respectively.  Anaerobic conditions decreased the  
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Table 2.2     Effect of oxygen on non-growing planktonic cultures.  P. aeruginosa cultures 
were grown in LB (+15 mM KNO3) under aerobic or anaerobic conditions, then exposed to 
COS-NO in PBS (pH 6.5) for 4 h under aerobic or anaerobic conditions.   
  
  
Growth 
Media 
Aerobic Exposure Anaerobic Exposure 
  
MBC  
(µg COS-
NO/mL) 
NO Dose 
 (µmol 
NO/mL) 
MBC  
(µg COS-
NO/mL) 
NO Dose*  
(µmol 
NO/mL) 
Nonmucoid 
Aerobic 100 0.022 ± 0.008 100 0.034 ± 0.017 
Anaerobic 100 0.022 ± 0.008 100 0.034 ± 0.017 
Mucoid 
Aerobic 100 0.022 ± 0.008 100 0.034 ± 0.017 
Anaerobic 200 0.044 ± 0.016 200 0.068 ± 0.033 
*Determined via amperometry.  Values are presented as means ± standard deviations for n=3 or 
more pooled experiments. 
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Table 2.3    Influence of oxygen on the inhibitory efficacy of COS-NO.  Bacteria cultures in 
mid-log growth were diluted to 2x106 CFU/mL in LB (+15 mM KNO3) with COS-NO and 
grown for 18 h under aerobic or anaerobic conditions.  The MIC was determined as the 
concentration of COS-NO which visibly inhibited growth.     
  Nonmucoid Mucoid 
  
MIC  
(µg COS-NO/mL) 
NO Dose  
(µmol NO/mL) 
MIC 
 (µg COS-NO/mL) 
NO Dose*  
(µmol NO/mL) 
Aerobic 800 0.022 ± 0.014 400 0.011 ± 0.007 
Anaerobic 100 0.014 ± 0.008 100 0.014 ± 0.008 
*Determined via amperometry.  Values are presented as means ± standard deviations for n=3 
or more pooled experiments. 
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MIC to 100 μg COS-NO/mL (0.014 µmol NO/mL) for both phenotypes. While the COS-NO dose 
required to inhibit growth was reduced in anaerobic environments, the NO dose delivered was not 
significantly lower, indicating that NO lost to reaction with oxygen accounts for the increased 
MICs against COS-NO under aerobic conditions. 
2.3.5 Inhibition of growth by COS-NO for clinical isolates, including tobramycin–resistant 
strains.   
To ensure that the increased inhibition of bacterial growth by COS-NO under anaerobic 
conditions was not solely a function of the laboratory P. aeruginosa strain used, 10 clinical isolates 
of P. aeruginosa were tested including mucoid, nonmucoid, and tobramycin-resistant isolates.  The 
amount of COS-NO required to inhibit growth under anaerobic conditions was less than or equal 
to those under aerobic conditions for all 10 isolates (Figure 2.5A).  There was no statistical 
difference in the NO-dose required to inhibit growth for most of the strains tested (Figure 2.5B).  
However, two isolates (denoted with * in Figure 2.5B) showed a statistically significant increase 
in NO payload required to inhibit growth under anaerobic conditions relative to aerobic conditions. 
Overall, COS-NO was more effective at inhibiting growth under anaerobic environments but the 
efficacy of NO was unchanged for most of the isolates tested.   
As with the laboratory strain, differences were seen between the mucoid and nonmucoid 
phenotypes (Figure 2.5).  Mucoid strains were more susceptible to COS-NO as indicated by the 
low MIC range (25-200 µg COS-NO/mL) relative to nonmucoid strains (MIC range 100-400 µg 
COS-NO/mL). No apparent differences were observed between tobramycin-susceptible and 
tobramycin-resistant strains of the same phenotype; however, more isolates would be needed to 
confirm the statistical significance of these trends.   
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Figure 2.5     MICs against clinical isolates of P. aeruginosa.  (A) The minimum 
concentration of COS-NO that visibly inhibited bacterial growth was determined for 
nonmucoid, mucoid, and tobramycin resistant isolates and (B) the corresponding NO dose for 
each isolate under aerobic and anaerobic environments.  All bacteria were grown and exposed 
in LB supplemented with nitrate (pH 6.5) for 18 h.   Statistically significant differences (p < 
0.05) between aerobic and anaerobic NO payloads are indicated (*). 
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2.3.7 Biofilm eradication by COS-NO and tobramycin 
As bacteria biofilms form predominantly in anaerobic pockets of mucus in the CF airways,2 
it was important to determine how oxygen concentrations affected the anti-biofilm activity of 
COS-NO.  Under aerobic conditions, highly viscous microcolony biofilms were formed (~250 µL  
in volume) with bacteria viability of 4.0 ± 0.6 ×108  and 2.5 ± 0.5 ×108 CFU/mL for nonmucoid 
and mucoid phenotypes, respectively.   Of note, nitrate supplementation was required to prevent 
phenotypic switching from the mucoid to the nonmucoid phenotype.44  Under anaerobic growth 
conditions, we were unable to form robust biofilms even after 7 d of growth.   
 Bacteria biofilms were exposed to COS-NO for 18 h in PBS (pH 6.5) under aerobic or 
anaerobic conditions.  The MBEC18h for both phenotypes was 4000 μg COS-NO/mL and 1000 μg 
COS-NO/mL (0.88 ± 0.33 and 0.34 ± 0.17 µmol NO/mL) in aerobic and anaerobic conditions, 
respectively (Table 2.4).  These results indicate that NO is equally effective at eliminating biofilms 
derived from nonmucoid and mucoid strains.  Moreover, NO is significantly more effective at 
eliminating biofilms in the absence of oxygen. 
The MBEC18h of tobramycin against biofilms was also determined to allow comparison of 
the NO treatment to current antibiotic therapies.   Under aerobic environments, the nonmucoid 
strain was eradicated at lower concentrations of tobramycin than the mucoid strain (200 and 800  
µg/mL, respectively) (Table 2.5).  Both strains required greater tobramycin levels (1600 µg/mL 
for both strains) to eradicate bacteria biofilms under anaerobic conditions. 
2.4 Discussion 
 We have previously reported on the antibacterial activity of NO against planktonic and 
biofilm based P. aeruginosa.13-14,37  However, little is understood regarding how oxygen and 
bacteria phenotype impact NO’s efficacy. Such knowledge is critical in the development of NO- 
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Table 2.4     Bactericidal efficacy of COS-NO against P. aeruginosa biofilms.  Biofilms were 
exposed to COS-NO in PBS (pH 6.5) for 18 h under aerobic or anaerobic conditions.  The 
MBEC18h was reported as the concentration of COS-NO required for 5-log reduction in biofilm 
viability. 
  Aerobic Exposure Anaerobic Exposure 
 MBEC  
(µg COS-NO/mL) 
NO Dose  
(µmol NO/mL) 
MBEC  
(µg COS-NO/mL) 
NO Dose*  
(µmol NO/mL)   
Nonmucoid 4000 0.88 ± 0.33 1000 0.34 ± 0.17 
Mucoid 4000 0.88 ± 0.33 1000 0.34 ± 0.17 
*Determined via amperometry.  Values are presented as means ± standard deviations for n=3 or 
more pooled experiments. 
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Table 2.5.  Bactericidal efficacy of tobramycin against P. aeruginosa biofilms.  Biofilms were 
exposed to tobramycin in PBS (pH 6.5) for 18 h under aerobic or anaerobic conditions.  The 
MBEC18h was reported as the concentration of COS-NO required for 5-log reduction in biofilm 
viability. 
  Aerobic Exposure Anaerobic Exposure 
 MBEC  
(µg/mL) 
MBEC 
(µmol/mL) 
MBEC 
(µg/mL) 
MBEC 
(µmol/mL)   
Nonmucoid 200 0.43 1600 3.42 
Mucoid 800 1.71 1600 3.42 
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based therapeutics for CF.   Water soluble NO-releasing chitosan oligosaccharides were used as 
the NO-release scaffold in the studies described herein due to the requirement that a 
macromolecular CF therapeutic be well tolerated and biodegradable.  Although chitosan is a 
known bactericidal agent, the reduced molecular weight (to ensure water solubility) and 2-
methylaziridine modification (for NO donor addition) resulted in a material with no bactericidal 
activity (Figures 2.3 and 2.4). 
 It is well-known that NO reacts with oxygen and superoxide to form highly reactive 
intermediates that facilitate bacteria killing through oxidative and nitrosative stresses.16,45  As 
oxygen plays an integral role in the antibacterial action of NO, anaerobic environments may reduce 
the biocidal efficacy of NO.17,46  However, NO also reacts with oxygen to form nitrate and nitrite.  
These seemingly paradoxical roles of oxygen on NO-mediated killing are not fully understood.  
To this end, we carried out electrochemical measurements of NO under aerobic and anaerobic 
conditions to quantify the amount of bioavailable NO.  Under aerobic conditions, the measured 
NO decreased by 35% compared to anaerobic conditions (Figure 2.2).  To elucidate the effects of 
oxygen availability in treatment media, bacteria were first grown aerobically and then exposed to 
COS-NO in aerobic or anaerobic PBS.  Identical concentrations of COS-NO were required to kill 
P. aeruginosa regardless of the treatment conditions. Due to reaction of NO with oxygen the 
bioavailable concentration of NO was slightly, but not significantly, higher under anaerobic 
conditions (Table 2.2).  As such, oxygen availability in the treatment media has no overall effect 
on the biocidal activity of NO-releasing chitosan oligosaccharides against planktonic P. 
aeruginosa. 
While oxygen concentration in the exposure media did not alter the bactericidal efficacy 
of NO, the presence of oxygen during bacterial growth did influence P. aeruginosa susceptibility 
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to NO.  Anaerobic growth conditions reduce the efficacy of current antibiotics by altering certain 
properties of the bacteria such as alginate production2 and metabolic rates.9  To separate these 
factors, MBC assays were performed under non-nutritive conditions to minimize the effects of 
bacteria metabolism on the bactericidal activity of NO. When bacteria were grown under anaerobic 
conditions, the efficacy of NO was decreased against the mucoid but not the nonmucoid 
phenotype, indicating that growing mucoid bacteria without oxygen significantly alters its defense 
against NO (Table 2.2).  Worliztsch et al. previously reported that P. aeruginosa produce a 
protective alginate exopolysaccharide that is 50% thicker when grown under anaerobic versus 
aerobic conditions.2  The increased thickness of this protective layer, characteristic of the mucoid 
phenotype, thus likely requires larger NO concentrations to penetrate the exopolysaccharide 
compared to nonmucoid P. aeruginosa. 
To study the role of anaerobic growth on the efficacy of NO, we evaluated the inhibition 
of P. aeruginosa growth by COS-NO in nutrient rich media under both aerobic and anaerobic 
conditions.   In contrast to the static conditions of MBC assays, bacteria are actively growing 
during inhibition assays.  Comparison of MIC values in oxygen and oxygen-free environments 
shows that the efficacy of COS-NO was enhanced under anaerobic conditions while there was no 
statistical difference in the NO dose.  This behavior was observed in the laboratory strains (Table 
2.3) and most of the clinical isolates tested (Figure 2.5), indicating that the efficacy of NO did not 
change but that the ability of COS-NO to deliver NO to the bacteria was improved in anaerobic 
conditions.  Current antibiotic treatments, including aminoglycosides and β-lactams, are less 
effective under anaerobic treatments because their mechanism of action requires actively dividing 
cells.47-48  In this respect, NO release provides a clear advantage over current treatments as the 
antibacterial action is not influenced by anaerobic environments.  
85 
 
Regardless of the antibacterial action against planktonic bacteria, the greatest challenge in 
reducing infection rates is the eradication of biofilms.1,49  As shown in Table 2.5, mucoid biofilms 
are significantly more resilient against tobramycin. Hentzer et al. previously attributed decreased 
antibiotic efficacy against mucoid strains to the overproduction of alginate.50  As has been 
previously reported,51-52 the low oxygen conditions of CF mucus further decreases the 
effectiveness of tobramycin (MBEC18h to 1600 µg/mL under anaerobic conditions).  While 
tobramycin is a highly effective anti-Pseudomonal agent, these factors compromise its ability to 
kill bacteria in CF airways.  In contrast, NO was equally effective at eradicating mucoid and 
nonmucoid biofilms and exhibited increased antibacterial activity in anaerobic versus aerobic 
conditions (Table 2.4).   
 Direct comparison of tobramycin with the NO-releasing chitosan oligosaccharides shows 
that NO is a more effective anti-biofilm agent under anaerobic conditions.  Indeed, the NO-dose 
required for biofilm eradication under anaerobic conditions is 0.34 ± 0.17 µmol NO/mL, tenfold 
lower than that of tobramycin (3.42 µmol/mL) (Tables 2.4 and 2.5).  Equally important, the amount 
of NO-releasing scaffold required for biofilm eradication is less than that of tobramycin.    
Together, this data suggests that NO may be a more effective therapeutic for eradicating P. 
aeruginosa biofilms in the CF lung, particularly under the low-oxygen conditions characteristic of 
CF mucus.    
 2.5 Conclusions 
 These studies examined the susceptibility of P. aeruginosa to NO-releasing chitosan 
oligosaccharides in conditions relevant to CF.  The antibacterial activity of NO-releasing chitosan 
oligosaccharides was enhanced in oxygen-free environments, despite a concomitant decrease in 
the number of possible mechanisms available to kill bacteria (i.e., less toxic byproducts from the 
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reactions of NO and oxygen).  Furthermore, the anti-biofilm action of NO was more effective than 
tobramycin and was not influenced by bacteria phenotype.  When combined with NO’s significant 
biocidal action against P. aeruginosa, these results suggest that NO-releasing chitosan 
oligosaccharides may represent a highly effective CF therapeutic.  We are currently seeking to 
enhance the NO payloads and study the effects of NO-release kinetics to improve the antibacterial 
efficacy of chitosan oligosaccharides while simultaneously evaluating cytotoxicity against human 
bronchial epithelial cultures.  
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CHAPTER 3:  DISRUPTION AND ERADICATION OF PSEUDOMONAS AERUGINOSA 
BIOFILMS USING NITRIC OXIDE-RELEASING CHITOSAN OLIGOSACCHARIDES 
3.1 Introduction 
Cystic fibrosis (CF) lung disease is caused by defective chloride transport, resulting in 
thickened, dehydrated mucus with altered biophysical properties such as increased viscoelasticity 
and osmotic pressure.1-2 One pathological consequence of the altered CF mucus is the inhibition 
of mucociliary clearance, ultimately resulting in increased airway inflammation and infection.3-4  
In addition to preventing the removal of pathogens, thickened CF mucus restricts bacteria motility 
and promotes P. aeruginosa biofilm formation.1  While biofilms are traditionally defined as 
antibiotic resistant, cooperative communities of bacteria within a protective matrix,5 they also 
constitute viscoelastic materials with well-defined physical and mechanical properties.6-7  
Strategies for treating P. aeruginosa biofilms and infections in the CF airways to date have focused 
on reducing bacteria viability through antibiotic treatment, specifically through the use of inhalable 
tobramycin.  Inhaled tobramycin is currently the only antibiotic recommended for both the 
treatment of initial8 and chronic9 P. aeruginosa infections in patients with CF.  While inhaled 
tobramycin is effective at eradicating bacteria within biofilms, it fails to physically remove the 
structural remnants of the biofilm from the airways.  Any bacteria that survive antibiotic treatment 
(e.g., persister cells) may initiate biofilm regrowth and the development of antibiotic-resistant 
infections.5,10-11  As such, degradation of the biofilm and its removal from the airway are essential 
to preventing recolonization.11-12  Physical disruption of the biofilm also increases the anti-biofilm 
efficacy of co-administered antibiotics, as antibiotic diffusion becomes enhanced in mechanically 
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weakened biofilms.13-15 Therefore, an ideal anti-biofilm therapeutic for CF would both eradicate 
bacteria and physically degrade the biofilm, facilitating clearance from the airway. 
In light of the importance of the viscoelastic properties of biofilms, much recent research 
has focused on quantifying how chemical and antibiotic treatments alter the mechanical properties 
of biofilms.  Lieleg et al.7 reported that gentamicin, colistin, ofloxacin, ethanol, and bleach did not 
alter P. aeruginosa biofilm elasticity when measured via rheometry.  In contrast, ciprofloxacin 
was shown to reduce the elasticity of P. aeruginosa biofilms to that of a viscous fluid.12  As each 
treatment elicits different effects, it is important to probe how antibacterial agents alter biofilm 
viscoelasticity for the development of any new therapies. 
Nitric oxide (NO) is an endogenously produced diatomic free radical with significant 
antibacterial activity against P. aeruginosa biofilms.16-18  At sub-bactericidal concentrations, NO 
has biofilm dispersing properties.19-20  The antibacterial efficacy of NO is derived from its ability 
to exert both nitrosative and oxidative stresses to bacterial membrane components (e.g. proteins, 
lipids, DNA) directly or via reactive byproducts including and dinitrogen trioxide and 
peroxynitrite.21-22  As the P. aeruginosa biofilm matrix is composed of proteins, extracellular 
DNA, and polysaccharides, it is likely that NO would alter or disrupt the structural integrity of 
these biofilms.23-24  Furthermore, atomic force microscopy has revealed that NO exposure causes 
structural damage to the membranes of planktonic Gram-negative bacteria, including P. 
aeruginosa.25  To determine the effects of NO on the viscoelastic properties of P. aeruginosa 
biofilms, macromolecular scaffolds capable of storing and controllably releasing NO were 
employed to locally deliver NO to bacterial biofilms.26-27  Chitosan oligosaccharides represent an 
attractive scaffold for pulmonary NO delivery due to several attractive properties including 
biodegradability, tolerability to mammalian cells, and ease of NO donor functionalization.17,28  
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Herein, we evaluate the utility of NO-releasing chitosan oligosaccharides to both eradicate and 
physically alter P. aeruginosa biofilms, with comparison to tobramycin.   
3.2 Materials and Methods 
3.2.1 Materials  
Tobramycin, medium molecular weight chitosan, and 2-methylaziridine were purchased 
from Sigma Aldrich (St. Louis, MO).  Sodium methoxide was purchased from Acros Organics 
(Geel, Belgium).  FluoSpheres carboxylate-modified microspheres (1 µm diameter) for use as 
tracer particles in microrheology experiments were purchased from Molecular Probes (Life 
Technologies, Carlsbad, CA).  Nitric oxide gas was purchased from Praxair (Sanford, NC).  
Calibration standard NO gas (26.85 ppm, balance N2), nitrogen (N2), and argon gases were 
purchased from Airgas National Welders (Durham, NC).  P. aeruginosa strain K (PAK) and the 
mucoid derivative (PAKmucA22) were a gift from Prof. Matthew Wolfgang from the University 
of North Carolina at Chapel Hill, Department of Microbiology and Immunology.  Phosphate 
buffered saline (PBS) was made with 10 mM sodium phosphate and adjusted to pH 6.5 to more 
closely resemble the CF airway.29  Luria-Bertani (LB) broth and agar were purchased from Becton, 
Dickinson, and Company (Franklin Lakes, NJ).  Biofilm growth media was prepared by diluting 
LB Broth 1:4 in water after which the pH was adjusted to 6.5 with 10 mM sodium phosphate.   
Milli-Q water with a resistivity of < 18.2 mΩ cm and a total organic content of < 6 ppb was 
prepared by purifying distilled water using a Millipore Milli-Q UV Gradient A-10 system 
(Bedford, MA).  All common laboratory salts, solvents, and reagents were purchased from Fisher 
Scientific (Pittsburgh, PA).  All materials were used without further purification.    
3.2.2 Synthesis of water-soluble 2-methylaziridine- modified chitosan oligosaccharides (COS) 
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Water-soluble chitosan oligosaccharides were synthesized by degrading medium 
molecular weight chitosan (2.5 g) in 50 mL of hydrogen peroxide (15 wt. %) for 1 h at 85 °C.   The 
resulting oligosaccharides were filtered to remove insoluble oligosaccharides, precipitated with 
acetone, collected via centrifugation (6500 × g, 10 min), and dried in vacuo.  The viscosity of the 
chitosan oligosaccharides was determined using an Ubbelohde viscometer in a solution of sodium 
chloride (0.20 M) and acetic acid (0.10 M) at 25 °C.  The classic Mark-Houwink equation (η = 
1.81 × 10-3 M0.93) was used to determine the molecular weight.30 
2-Methylaziridine was grafted to the chitosan oligosaccharides as previously described.17  
Briefly, the water soluble chitosan oligosaccharides (0.5 g) were dissolved in water (10 mL) after 
which a solution of concentrated hydrochloric acid (27.5 µL), water (250 µL), and 2-
methylaziridine (356 µL) was added dropwise at room temperature.  The solution was stirred for 
5 d at 25 °C followed by 24 h at 70 °C.  The 2-methylaziridine-modified chitosan oligosaccharides 
(COS) were then collected via precipitation in acetone, washed copiously with ethanol, and dried 
in vacuo at room temperature.  1H NMR data of COS: (400 MHz, D2O, δ): 0.8–1.1 
(NH2CH(CH3)CH2NH), 1.9 (C7: CHNHCOCH3), 2.3–2.9 (NH2CH(CH3)CH2NHCH, C2: 
NH2CH(CH3)CH2NHCH), 3.3–4.0 (C3, C4, C5, C6: OHCH, OCHCH(OH)CH(NH2)CH, 
OHCH2CH, OHCH2CH), 4.4 (C1: OCH(CHNH2)O). 
3.2.3 N-diazeniumdiolate modification of chitosan oligosaccharides 
N-diazeniumdiolate NO donors were formed on the secondary amines of COS via exposure 
to high pressures of NO gas.17  Briefly, 2-methylaziridine-modified chitosan oligosaccharides (45 
mg) were dissolved in water (900 µl), methanol (2.10 mL), and sodium methoxide (5.4 M, 75 µL) 
in 1 dram glass vials.  The vials containing the COS solution were placed in a stainless steel reactor.  
Oxygen was removed from the system by purging with argon via three short purges (15 s, 8 bar) 
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followed by three long purges (10 min, 8 bar).  After the final purge, the vessel was filled with NO 
gas (10 bar) that had been purified in a potassium hydroxide chamber.  Solutions were stirred at 
room temperature for 72 h.  Following N-diazeniumdiolate formation, unreacted NO was removed 
from solution via the same argon purging procedure used to remove oxygen.  The resulting 
solutions of NO-releasing chitosan oligosaccharides (COS-NO) were centrifuged (6500 × g, 15 
minutes), precipitated with 3 mL of acetone, collected via centrifugation, and dried in vacuo 
overnight at room temperature.  The solid COS-NO was stored in a vacuum sealed bag at -20°C 
until use.   
3.2.4 Characterization of nitric oxide release 
  Real-time NO-release kinetics from COS-NO were determined using at a Sievers Nitric 
Oxide Analyzer (Boulder, CO).  Prior to analysis, the instrument was calibrated with air passed 
through a NO zero filter (0 ppm NO) and 25.87 ppm of NO standard gas (balance N2).  Solid COS-
NO (1 mg) was added to 30 mL of deoxygenated PBS (37 °C, pH 6.5).  Nitric oxide released from 
COS-NO was carried to the analyzer using nitrogen gas flowing through the solution at rate of 80 
mL/min.  Additional nitrogen was supplied to the reaction flask to achieve the required instrument 
collection rate of 200 mL/min.  Analysis was terminated when NO levels decreased below 10 
ppb/mg chitosan oligosaccharide.   
3.2.5 Biofilm growth and eradication assays 
Frozen cultures of P. aeruginosa were grown overnight in LB broth, diluted 1:100 in 50 
mL of fresh LB broth, and grown to mid-log phase (OD600=0.25).   Rapidly growing cultures were 
diluted to 106 CFU/mL (1:100 dilution) in biofilm growth media.  Viscous biofilms were grown 
in 12-well microtiter plates at 37°C for 72 h with gentle shaking (100 rpm).  Biofilms appeared as 
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viscous bacterial aggregates (i.e. microcolonies) floating in the growth media.  These biofilms 
were mechanically robust (i.e. they could not be disrupted by vigorous pipetting), indicating the 
formation of a suitable experimental matrix.31  Biofilms were extracted from the growth media via 
pipetting and then washed by ejection into PBS (pH 6.5). The biofilms were subsequently added 
to a solution of PBS (pH 6.5) containing COS-NO, COS, or tobramycin and incubated for 18 h at 
37 °C with gentle shaking (100 rpm).  The biofilms were again washed in PBS (pH 6.5) to remove 
excess antibacterial agent prior to further analysis. 
Following exposure to the test agents, biofilms were plated and enumerated to determine 
the minimum biofilm eradication concentration (MBEC), defined herein as the minimal 
concentration of drug required for a 5-log reduction in bacteria viability.  Freshly washed biofilms 
were gently sonicated for 10 min and vortexed to disrupt the matrix.  The resulting solutions were 
serially diluted in PBS, spiral plated on LB Agar, and incubated at 37°C for 24 h. Bacteria colonies 
were quantified using a Flash & Go colony counter (IUL, Farmingdale, NY).  This method has an 
inherent limit of detection of 2.5×103 CFU/mL.32 
3.2.6 Multiple-particle tracking microrheology 
Biofilms were grown as described above except with the incorporation of fluorescent tracer 
particles.  Fluorescent tracer particles were diluted 1:1000 from their stock solution (2 wt. %) into 
the biofilm growth media prior to the addition of planktonic bacterial. Biofilms were exposed to 
antibacterial agents (i.e. COS-NO, COS, or tobramycin) as in the MBEC assays.  Following 
treatment, the biofilms were placed in a transparent sample holder.  Specifically, the biofilms were 
sealed between a glass microscope slide and coverslip with two sheets of parafilm acting as a 
spacer.  The sample holders were sealed on using parafilm to minimize sample evaporation.  Tracer 
particle movement was recorded at 60 frames/s for 30 s with a Flea3 grey scale camera (Point 
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Grey, Richmond, Canada) mounted on a Nikon Eclipse TE2000-E inverted microscope at 40× 
magnification. The tracer particle displacement as a function of time was quantified using Video 
Spot Tracker software (Center for Computer Integrated Systems for Microscopy and 
Manipulation, University of North Carolina at Chapel Hill).  
The mean squared displacement (MSD) of each tracer particle was calculated from the 
displacement of individual particles as a function of time as previously described.33  Briefly, the 
MSD was determined according to: 
MSD =  
1
𝑁−𝜏
∑ [(𝑥(𝑡𝑖 + 𝜏) − 𝑥(𝜏))
2
+ (𝑦(𝑡𝑖 + 𝜏) − 𝑦(𝜏))
2
]𝑁−𝜏𝑖=𝑡  (Eq. 1) 
where τ represents time lag, ti is the time at the start of the video (0.00 s), and N is the total number 
of frames in a video (1800 for all experiments). 
Due to biofilm heterogeneity, the MSD of all tracer particles were ensemble averaged to 
achieve meaningful MSD curves.33  For each condition tested, tracer particle displacement was 
measured in 15 different viewing areas of three separate biofilms, resulting in ensemble averaging 
of at least 200 particles per treatment.  The ensemble averaged MSD was calculated as previously 
reported.33  For clarity, MSD values were analyzed at τ = 0.83 s.  At this time point (MSDτ=0.83s), 
the accuracy of the camera speed does not affect the measurement, and thermal drift is minimized.  
All MSD values are reported as the mean ± standard error of the mean (SEM).  Due to the large 
sampling size, the error is often too small to be visible on the figures presented herein.   
3.2.7 Measurement of distance between nearest neighbor particles 
The average distance between nearest neighbor particles was determined to quantify 
contraction and expansion of the bacterial biofilms.34  Distances between nearest neighbor tracer 
particles were calculated according to the equation: 
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𝑅12 = √(𝑥2 − 𝑥1)2 + (𝑦2 − 𝑦1)2  (Eq. 2) 
where R12 represents the distance between beads, 𝑥1 and 𝑦1 are the location of tracer particle 1, 
and 𝑥2 and 𝑦2 are the location of tracer particle 2.  The smallest R12 value for each bead was then 
selected as the distance between nearest neighbor particles.   
3.3 Results 
Water soluble chitosan oligosaccharides were synthesized from chitosan via oxidative 
degradation.35  The molecular weight of the chitosan oligosaccharides was determined to be 4.410 
± 0.037 kDa by the classic Mark-Houwink Equation.30  To impart NO-release capabilities, 2-
methylaziridine-modified chitosan oligosaccharide scaffolds (COS) were reacted with NO gas at 
high pressure.  The resulting N-diazeniumdiolate-modified chitosan oligosaccharides (COS-NO) 
released a total of 0.78 ± 0.09 µmol NO/mg over a duration of 10.7 ± 1.1 h in PBS (pH 6.5, 37 °C) 
(Figure 3.1, Table 3.1).  The half-life of NO release was 0.62 ± 0.08 h. 
3.3.1 Viscoelastic properties of P. aeruginosa biofilms   
Fluorescent tracer particles were incorporated into P. aeruginosa biofilms during biofilm 
formation to determine the viscoelastic properties of bacterial biofilms (Figure 3.2).  Tracer 
particles within the biofilms exhibited decreased diffusion compared to tracer particles in solutions 
of planktonic bacteria (Figure 3.3).  The diffusion exponent (α) was derived to approximate 
viscoelasticity according to MSD ∝ tα.  Through this relationship, purely viscous solutions are 
defined as having diffusion exponents of one, while purely elastic solids exhibit diffusion 
coefficients of zero.  Therefore, diffusion coefficients of viscoelastic materials range from zero to 
one.36  The displacement of tracer particles in solutions of planktonic bacteria increased linearly  
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Figure 3.1 Chemiluminescence detection of NO release from COS-NO.  The NO release 
from 1 mg of COS-NO was determined in deoxygenated PBS (pH 6.5) for comparison with 
other NO-releasing systems.  The (A) NO total and (B) NO flux of representative measurements 
are shown. 
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Table 3.1     Nitric oxide-release properties of COS-NO in PBS (pH 6.5, 37 °C) as 
determined by chemiluminescence detection.   Values are presented as means ± standard 
deviations for n=3 pooled experiments. 
NO Total 
(µmol NO/mg COS-NO) 
Duration 
(h) 
Half-Life 
(h) 
Max Flux 
(PPB/mg) 
0.78 ± 0.09 10.7 ± 1.1 0.62 ± 0.08 3200 ± 600 
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Figure 3.2 Incorporation of fluorescent tracer particles in P. aeruginosa biofilms.  (A) 
Planktonic bacteria (106 CFU/mL) and fluorescent tracer particles were incubated in 25% LB at 
pH 6.5.  (B) After 72 h of growth at 37 °C, microcolony biofilms formed with tracer particles 
embedded throughout the biofilm.  (C)  Biofilms were washed in PBS and exposed to 
antibacterial treatments for 18 h prior to (D) analysis by particle tracking microrheology. 
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Figure 3.3 Microrheology of P. aeruginosa biofilms.    (A) Ensemble average MSD of 
tracer particles in solutions of planktonic bacteria and biofilms show incorporation of particles 
into the biofilm.  Diffusion coefficients of viscous solutions (α = 1) and elastic solids (α = 0) 
are superimposed on MSD plots for reference.   Distributions of MSDτ=0.83s for tracer 
particles in (B) biofilms compared to (C) solutions of planktonic bacteria.  The mean of each 
distribution is marked with a vertical dotted line. 
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with time (α = 1.05 ± 0.13), indicating that they were moving in a purely viscous solution.  In 
contrast, the measured slope for tracer particles within P. aeruginosa biofilms was significantly 
lower (α = 0.62 ± 0.14), indicating that the medium surrounding the particles was both viscous and 
elastic.  P. aeruginosa biofilms were thus determined to be viscoelastic materials with properties 
distinct from solutions of planktonic bacteria.   
Histograms were used to visualize the distribution of the MSDτ=0.83s and analyze biofilm 
heterogeneity.  The MSDτ=0.83s of tracer particles within P. aeruginosa biofilms were highly 
heterogeneous, as indicated by the non-Gaussian distribution of MSDτ=0.83s (Figure 3.3 B).  The 
average MSDτ=0.83s was heavily influenced by fast moving particles with the mean (0.24 ± 0.01 
µm2) substantially greater than the mode (0.00 – 0.02 µm2).  This specific type of heterogeneity 
indicates that some tracer particle were moving inside large pores or water channels within the 
biofilms.37  Tracer particles in solutions of planktonic bacteria exhibited a Gaussian distribution of 
MSDτ=0.83s with mean (1.53 ± 0.04 µm
2) and mode (1.40 – 1.68 µm2) approximately equal (Figure 
3.3 C).   
3.3.2 Tobramycin treatment of P. aeruginosa biofilms 
As tobramycin is the current standard for the treatment of P. aeruginosa infections in CF 
patients,8-9 the effects of tobramycin on the mechanical properties of P. aeruginosa biofilms were 
determined as a comparison to NO therapy.  Tobramycin was found to eradicate biofilms (i.e. to 
reduce bacteria viability by 5 logs over 18 h) at a concentration of 200 µg/mL (Figure 3.4 A.).   
 The MSD plots of biofilms treated with tobramycin appeared similar to untreated controls, 
indicating that tobramycin did not alter the viscoelastic properties of the biofilm (Figure 3.3 B).  
Over a timescale of 3 decades (0.017 – 3.33 s), no significant differences in the diffusion 
coefficients of untreated and tobramycin-treated biofilms were observed (Table 3.2).  While the 
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Figure 3.4 Treatment of P. aeruginosa biofilms with tobramycin.  (A) Biofilm viability 
after exposure to tobramycin for 18 h.  The MBEC of tobramycin was 200 µg/mL.  (B) MSD 
values of tracer particles in biofilms grown with nomucoid (motile) P. aeruginosa, mucoid 
(non-motile) P. aeruginosa, and nonmucoid P. aeruginosa treated with 50 µg/mL of 
tobramycin. (C) MSDτ=0.83s untreated nonmucoid and mucoid P. aeruginosa biofilms as 
well as nonmucoid P. aeruginosa biofilms exposed to tobramycin for 18 h.  All MSD were 
determined by tracking particles in 15 distinct areas of 3 separate biofilms and are plotted as 
ensemble average MSD ± SEM.   
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 temporal dependency of particle diffusion was unchanged by tobramycin treatment, the magnitude 
of the MSD was reduced at all time points for treated biofilms.  This decrease was independent of 
 tobramycin concentration (Figure 3.4 B).  For tobramycin-treated biofilms, the MSDτ=0.83 ranged 
from 0.154 ± 0.009 µm2 to 0.183 ± 0.009 µm2, compared to 0.241 ± 0.007 µm2 for untreated 
biofilms (Figure 3.4 C).  We hypothesized that the decrease in MSD magnitude was due to loss of 
bacteria motility upon treatment with tobramycin.  Unlike traditional macro- and microrheology, 
which solely measure the bulk viscoelastic properties of a material, multiple-particle tracking 
microrheology quantifies the movement of particles within the biofilms.  Tracer particle movement 
is influenced by the movement (i.e. swimming or motility) of bacteria as well as the viscoelastic 
properties of the biofilm matrix.  Therefore, cessation of bacteria motility upon killing would 
reduce the MSD of particles within the biofilm.   
To confirm that the decrease in MSD was related to reduced bacteria motility, biofilms 
were grown with a strain of non-motile, mucoid P. aeruginosa.38  The magnitude of the MSD of 
tracer particles in biofilms comprised of non-motile bacteria (i.e. bacteria that are mucoid or have 
lost motility due to tobramycin-induced cell death) was indeed lower than that of tracer particles 
in biofilms of motile bacteria (Figure 3.4 B).  The diffusion coefficient of mucoid biofilms was 
0.70 ± 0.17, similar to the tobramycin-treated biofilms (range 0.56 ± 0.02 to 0.70 ± 0.12) (Table 
3.2).  While biofilms grown from mucoid P. aeruginosa have a different matrix composition than 
the nonmucoid strain, the similar diffusion coefficients for all three biofilms (i.e. nonmucoid, 
mucoid, and tobramycin-treated) indicated that the reduction in MSDτ=0.83 magnitude upon 
treatment with tobramycin was the result of bacteria motility loss, and not tobramycin-induced 
alterations in the biofilm viscoelasticity.  The decrease in the MSDτ=0.83 was independent of 
tobramycin concentration over the range of ¼ – 4x the MBEC (Figure 3.4 C).  At the lowest  
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Table 3.2.     Diffusion exponents (α-values) of P. aeruginosa biofilms treated with tobramycin. 
Tobramycin (µg/mL) α 
0 0.62 ± 0.14 
50 0.70 ± 0.12 
100 0.56 ± 0.02 
200 0.66 ± 0.08 
400 0.68 ± 0.10 
800 0.59 ± 0.06 
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concentration tested (50 µg/mL), ~99% of the bacteria in the biofilm were no longer viable and 
therefore lacked motility.  Therefore, the decrease in bacteria viability was substantial enough to 
alter the MSDτ=0.83 of tracer particles within the tobramycin-treated biofilms, even at the lowest 
concentration tested.  Overall, the bacteria motility accounted for 31.8 ± 1.6% of the MSDτ=0.83 
based on the decrease in the magnitude of MSDτ=0.83 of tobramycin-treated and mucoid P. 
aeruginosa biofilms 
3.3.3 Treatment of P. aeruginosa biofilms with COS and COS-NO 
At the largest concentration tested (16 mg/mL), the COS scaffold decreased the bacteria viability 
by three logs without fully eradicating the P. aeruginosa biofilm (Figure 3.5 A).  While chitosan 
in general is a known antimicrobial,39 the anti-biofilm efficacy of the chitosan oligosaccharides 
was significantly reduced, as has previously been demonstrated.40  Addition of NO to the COS 
scaffold significantly improved of anti-biofilm activity, eradicating biofilms at 4 mg/mL, which 
corresponds to a bactericidal NO dose of 3.1 ± 0.4 µmol/mL (Figure 3.5 A).   
Despite low biofilm eradication capabilities, the COS scaffold significantly altered the 
viscoelasticity of P. aeruginosa biofilms.  Treatment of biofilms with 2 mg/mL COS decreased 
the magnitude of the MSDτ=0.83s by two logs (to 0.0031 ± 0.0002 µm
2) compared to untreated 
controls (MSDτ=0.83s = 0.241 ± 0.007 µm
2), with no further reduction in the MSDτ=0.83 when the 
concentration of COS was increased to 16 mg/mL (Figure 3.5 B).  While the MSD (at all τ) of 
untreated biofilms exhibited a temporal dependency (revealing partial viscosity), treatment with 
COS over the concentration range of 1 – 16 mg/mL eliminated this time dependence (Figure 3.5 
C).   The diffusion coefficients of COS treated biofilms ranged from 0.03 ± 0.02 to 0.14 ± 0.02, a 
significant reduction compared to untreated biofilms (0.62 ± 0.14) (Table 3.3).  Treatment with  
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Figure 3.5 Treatment of P. aeruginosa biofilms with COS and COS-NO.   (A) Biofilm 
viability following exposure to COS or COS-NO for 18 h.  While COS did not fully eradicate 
biofilms, the MBEC of COS-NO was 4 mg/mL (NO dose of 3.1 ± 0.4 µmol).   (B) MSDτ=0.83s 
of biofilms treated with COS and COS-NO.  The MSDτ=0.83s of untreated biofilms is indicated 
as a horizontal line.   Note the logarithmic scale of the y-axis.  (C) The MSD values of 
biofilms treated with COS and (D) COS-NO.  All MSD were determined by tracking particles 
in 15 distinct areas of 3 separate biofilms and are plotted as ensemble average MSD ± SEM.  
Diffusion coefficients of viscous solutions (α = 1) and elastic solids (α = 0) are superimposed 
on MSD plots for reference. 
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Table 3.3     Diffusion exponents (α) of P. aeruginosa biofilms treated with COS and COS-NO.  
The total NO released from COS-NO at each concentration is also provided. 
Dose 
(mg/mL) 
COS 
α 
COS-NO 
α 
NO 
µmol/mL 
0 0.62 ± 0.14 0.62 ± 0.14 n/a 
1 0.07 ± 0.04 0.68 ± 0.04 0.8 ± 0.1 
2 0.10 ± 0.20 0.74 ± 0.14 1.6 ± 0.2 
4 0.03 ± 0.02 0.64 ± 0.10 3.1 ± 0.4 
8 0.07 ± 0.04 0.55 ± 0.13 6.2 ± 0.7 
12 0.14 ± 0.02 0.91 ± 0.06 9.4 ± 1.1 
16 0.11 ± 0.12 1.00 ± 0.11 12.5 ± 1.4 
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COS clearly transformed P. aeruginosa biofilms into nearly elastic solids with almost no viscous 
component.   
While the COS scaffold decreased both the MSDτ=0.83s and diffusion coefficients of tracer 
particles within P. aeruginosa biofilms at all concentrations, NO-releasing COS (i.e., COS-NO) 
induced a dose-dependent response in biofilm viscoelasticity.   Both the MSDτ=0.83s and diffusion 
coefficients decreased with increasing COS-NO at concentrations ≤ 8 mg/mL (Figure 3.5 B, Table 
3.3).  Tracer particles in biofilms exposed to COS-NO exhibited substantially higher MSDτ=0.83s 
and diffusion coefficients than those in biofilms exposed to the same concentrations of the COS 
scaffold (Figure 3.5 B).  At concentrations ≥ 12 mg/mL COS-NO, both the MSDτ=0.83s and 
diffusion coefficients increased substantially above those of untreated biofilms (Figure 3.5 B, 
Table 3.3).  The increase in both of these parameters indicates degradation of the viscoelastic 
properties of the biofilm.  As biofilm degradation occurred above the MBEC of COS-NO (4 
mg/mL), destruction of the physical properties of the biofilm required a larger dose of NO (9.4 ± 
1.1 µmol/mL) than biofilm eradication (3.1 ± 0.4 µmol/mL).    
3.3.4 Heterogeneity of treated P. aeruginosa biofilms 
Sample heterogeneity has been correlated with increased viscoelasticity for complex biological 
materials such as sputum.33,41  The effect of antibacterial treatment on biofilm heterogeneity was 
thus evaluated at concentrations in excess of the MBEC.  As expected, tobramycin had no 
observable effect on the heterogeneity of biofilms.  While tobramycin treatment decreased the 
average MSDτ=0.83s, concentrations of tobramycin in excess of the MBEC did not alter the shape 
of the MSDτ=0.83s distributions (Figure 3.6 A-C) compared to untreated biofilms (Figure 3.3-B);  
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Figure 3.6. Histograms of biofilm heterogeneity after treatment.  The distributions of 
MSDτ=0.83s of individual tracer particles in (A-C) biofilms treated with tobramycin, (D-F) 
COS, and (G-I) COS-NO at concentrations above the MBEC values.  The mean of each 
distribution is marked with a vertical dotted line.  
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
1
2
3
4
5
6
7
8
9
10
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
1
2
3
4
5
6
7
8
9
10
MSD =0.83s (m
2
)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
120
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
120
MSD =0.83s (m
2
)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
120
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
35
MSD =0.83s (m
2
)
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
B
C
E
F
H
I
3x 
MBEC
4x 
MBEC
1200 µg/mL 16 mg/mL
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
A D G
2x 
MBEC
Tobramycin COS COS-NO
400 µg/mL
800 µg/mL
8 mg/mL
12 mg/mL
8 mg/mL
12 mg/mL
16 mg/mL
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
35
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
35
MSD =0.83s (m
2
)
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
35
MSD =0.83s (m
2
)
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
5
10
15
20
25
30
35
MSD =0.83s (
2
)
%
 T
ra
c
e
r 
P
a
rt
ic
le
s
114 
 
both exhibited MSDτ=0.83s distributions skewed such that the modes were substantially lower than 
the mean.   
Treatment with COS and COS-NO resulted in opposing effects on the MSDτ=0.83s 
distributions of P. aeruginosa biofilms.  The COS scaffold constrained tracer particle movement, 
decreasing the width of the MSDτ=0.83s distribution and reducing biofilm heterogeneity (Figure 3.6 
D-F).  Alternatively, treatment with COS-NO at concentrations above the MBEC resulted in 
degradation of the biofilm and increased heterogeneity.  Treatment with 8 mg/mL COS-NO 
showed little alteration in the MSDτ=0.83s distribution (Figure 3.6 G) compared to untreated controls 
(Figure 3.3-B).  However, exposure to 12 mg/mL COS-NO resulted in a bimodal MSDτ=0.83s 
distribution (Figure 3.3-H).  When treated with 16 mg/mL COS-NO, the MSDτ=0.83s distribution 
was Gaussian and centered around 1 µm2 (Figure 3.6-I).  
3.3.5 Quantification of biofilm contraction 
The average distance between nearest neighbor particles was determined to quantify biofilm 
expansion and contraction after treatment.  For untreated biofilms, the average distance between 
nearest neighbor particles was 21.7 ± 0.8 µm (indicated by the horizontal line in Figure 3.7).  At 
concentrations ranging from ½ to 4-times the MBEC, tobramycin exposure did not alter the 
average distance between nearest neighbor particles compared to the untreated biofilm (Figure 3.7 
A), indicating that tobramycin treatment had little effect on the contraction or expansion of the 
biofilm.  
In contrast, COS and COS-NO treatment resulted in significant alterations to the biofilm 
structure.  The COS scaffold reduced the average distance between nearest neighbor tracer 
particles compared to untreated biofilms with ~50% biofilm contraction that was independent of 
COS concentration from 1 – 16 mg/mL (Figure 3.7 B).   Treatment with COS-NO exhibited a  
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Figure 3.7 Average distances between nearest neighbor particles following treatment with 
(A) tobramycin and (B) chitosan oligosaccharides.   Average separation between tracer 
particles in untreated biofilms is indicated by a horizontal line. All separation distances were 
quantified in 15 distinct areas of 3 separate biofilms and are plotted as ensemble average MSD 
± SEM. 
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dose-dependent response on tracer particle separation (Figure 3.7 B).  At concentrations below 8 
mg/mL, treatment with COS-NO had no effect on the distance between nearest neighbor tracer 
particles.  At larger concentrations (i.e. ≥ 12 mg/mL), the average particle separation increased 
significantly.  As expected, tracer particle separation increased as the biofilm degraded. The 
concentration of COS-NO resulting in increased separation of nearest neighbor particles correlated 
with the concentration required for partial destruction of the viscoelastic properties of the biofilm 
(12 mg/mL). 
3.6 Discussion 
An ideal treatment for P. aeruginosa biofilms in CF patients would reduce bacteria 
viability while physically disrupting the biofilm in order to ease biofilm removal and prevent 
regrowth.  As such, it is important to characterize the effects of antibacterial therapeutics on the 
viscoelastic properties of P. aeruginosa biofilms.  While highly effective at eradicating bacteria, 
tobramycin does not alter the biophysical properties of P. aeruginosa biofilms.  Indeed, our results 
indicate that treatment with tobramycin neither alters the distance between nearest neighbor tracer 
particles (Figure 3.7) nor the diffusion coefficient of tracer particles within biofilms (Table 3.2).  
Of note, a decrease in particle diffusion (i.e., the MSD at all τ) was observed and attributed to the 
loss of bacteria motility rather than alterations in the physical properties of the biofilm (Figure 
3.4). 
 In comparison to tobramycin, NO released from the chitosan oligosaccharides both 
eradicated bacteria and degraded the biofilm physical properties (Figure 3.5).  At concentrations 
above the MBEC (i.e., ≥ 12 mg/mL), the COS-NO significantly compromised the structural 
integrity of the biofilms, as evidenced by increases in the MSDτ=0.83s and diffusion coefficients of 
tracer particles within treated biofilms (Figure 3.5, Table 3.3).  The increased tracer particle 
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movement may be attributed to either an overall loosening of the biofilm or heterogeneous 
destruction of the biofilm matrix.  In the case of uniform biofilm loosening, the diffusion of all 
particles would increase, shifting MSDτ=0.83s distributions to larger values without changing the  
overall shape of the distribution.  However, the observed bimodal distribution is consistent with 
destruction of discrete segments of the biofilm, where some of the tracer particles remained 
constrained in the biofilm while a second population of tracer particles experienced increased 
diffusion outside of the biofilm (Figure 3.6-H).   Further increasing the concentration of COS-NO 
resulted a Gaussian MSDτ=0.83s distribution centered around 1 µm
2, suggestive of complete biofilm 
destruction and free diffusion of the tracer particles in PBS (Figure 3.6-I).  These results indicate 
that NO does not cause a gradual loosening of the biofilm but rather destroys segments of the 
biofilms and is capable of complete biofilm destruction. 
While the mechanism of NO-mediated destruction of the biofilm is likely complex (i.e. due 
to multiple factors), NO has been shown to alter the biological macromolecules that constitute the 
majority of the biofilm matrix.21,23-24,27  For example, DNA is essential to the formation of P. 
aeruginosa biofilm42 with cleavage of  DNA by DNase decreasing the structural integrity of such 
biofilms.43   As in vitro studies have shown that exogenous NO damages and cleaves DNA,44-45 it 
is likely that NO-mediated destruction of DNA would physically degrade P. aeruginosa biofilms. 
Nitric oxide and its reactive intermediates also depolymerize polysaccharides,46 which may further 
explain NO’s ability to reduce biofilm viscoelasticity through damage to alginate, Psl, and Pel 
structural biofilm polysaccharides.47  
While NO represents a promising therapeutic for the physical degradation of P. aeruginosa 
biofilms, it is currently limited by the effects of the COS scaffold as the chitosan treatment alone 
results in biofilm contraction regardless of concentration (0.5 – 16 mg/mL).  Such contraction 
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(Figure 3.7) parallels increased biofilm elasticity and decreased particle diffusion (Table 3.3, 
Figure 3.5), which correlates to physical entanglement of polymers and effective cross-linking 
(e.g. covalent or hydrogen bonding, electrostatic interactions) in both ideal polymer and biological 
systems.47-49  As the P. aeruginosa biofilm matrix is comprised predominantly of anionic 
macromolecules,23 the introduction of cationic chitosan alters the electrostatics of the biofilm and 
potentially enhances cross-linking.  To further improve the efficacy these NO-releasing 
therapeutics, scaffolds that do not increase the elasticity of bacterial biofilms should be 
investigated.  As the cationic nature of chitosan likely contributes to biofilm cohesion, modifying 
the chitosan oligosaccharide scaffold with anionic moieties may reduce these effects.  
Furthermore, the biofilm disrupting capabilities of NO-releasing chitosan oligosaccharides may be 
improved by adjusting the NO payload.  For example, increasing the NO storage should reduce 
the concentration of COS-NO required for biofilm degradation, thereby minimizing any 
underlying effects of the scaffold. 
3.7 Conclusions 
 This work describes the ability of NO-releasing chitosan oligosaccharides to act as dual-
functioning therapeutics which eradicate and physically degrade P. aeruginosa biofilms.  At 
concentrations in excess of those required for eradication, NO segmentally destroyed P. 
aeruginosa biofilms.  As the physical properties of biofilms are related to antibiotic efficacy and 
potential for regrowth, the ability to physical degrade the bacterial biofilms represents a significant 
improvement over tobramycin, which failed to alter biofilm viscoelasticity.  The chitosan 
oligosaccharides used as NO-donor vehicles actually enhanced biofilm elasticity, potentially 
mitigating the biofilm degrading activity of NO.  Therefore, future studies investigating the 
biophysical effects of NO on biofilms should utilize more inert scaffolds. 
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CHAPTER 4:  NITRIC OXIDE-RELEASING CHITOSAN OLIGOSACCHARIDES AS 
MUCOLYTIC AGENTS 
4.1 Introduction 
 Cystic fibrosis disease pathogenesis is primarily dictated by the viscoelastic properties of 
airway mucus.  Dysfunction of the cystic fibrosis transmembrane regulator (CFTR) protein results 
in sodium hyperabsorption and subsequent airway dehydration, ultimately leading to inhibited 
mucociliary clearance.1 Accumulation of a concentrated mucus layer with increased viscosity and 
elasticity cultivates bacterial infections.2-3  While antibiotic treatments attempt to eradicate bacteria 
in the airways, mucolytic agents are designed to prevent bacterial colonization by disrupting the 
stagnant mucus layer, thereby improving clearance.4  Conventional mucolytics such as L-cysteine, 
N-acetylcysteine (NAC), and dithiothreitol improve clearance by reducing mucin disulfide bonds, 
thus decreasing entanglement of high molecular weight mucins.5-6  The most popular thiol-based 
mucolytic, NAC, has proven to reduce mucus viscoelasticity by this pathway both in vitro7-9 and 
in vivo.10  Unfortunately, improvements in lung function have not been demonstrated in clinical 
trials.11  The only mucolytic agent currently available for the treatment of CF is dornase alfa, a 
recombinant human deoxyribonuclease (DNase) enzyme that depolymerizes extracellular DNA in 
CF mucus.  Dornase alpha has been shown to both reduce mucus viscoelasticity12-14 and improve 
pulmonary function.13,15-17  
 Unfortunately, dornase alfa is only effective in 10% of CF patients.18 As such, the 
development of new mucolytic agents capable of reducing mucus viscosity and elasticity remains 
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critical.  Inhalation of nitric oxide (NO) gas has been proposed as a mucolytic therapeutic.19  In 
thoroughbred horses suffering from excess mucus accumulation in the airways, inhalation of NO 
gas (100 breaths, 5,000-10,000 ppm) resulted in the secretion of non-viscous fluids from the 
nares.19   Multiple treatment cycles over several weeks decreased airway mucus accumulation in 
25 of 27 horses.  Of note, a lack of controls (i.e., measurement of mucus accumulations in non-
treated horses) reduced the impact of this study.  
While the in vivo efficacy of NO has been demonstrated,19 the potential mechanisms of 
NO’s mucolytic activity have not been characterized systematically.   Disulfide bond cleavage has 
been proposed as NO reacts with thiols to form S-nitrosothiols.19-20  Nitric oxide also 
depolymerizes O-linked polysaccharides,21 thereby likely altering the glycosylated domains of 
mucins.  While disruption of the glycosylated domains would alter intra-mucin interactions, the 
effects of NO on gel formation and mucus viscoelasticity are not clear. Similar to dornase alfa, 
NO could potentially reduce mucus viscoelasticity by damaging and/or cleaving DNA.22-23 
Strategies for controllably storing and releasing NO are required to effectively develop NO 
as a mucolytic therapeutic.  Compared to small molecule donors, NO released from 
macromolecular scaffolds has been demonstrated to improve bactericidal efficacy against both 
planktonic cultures and biofilms.24-26  Additionally, continuous NO delivery to the airways may be 
achieved by intermittent treatment rather than continuous inhalation (i.e., from a pressurized gas 
cylinder) due to prolonged NO release afforded by macromolecular scaffolds. 
Chitosan oligosaccharides have been purposed as scaffolds for pulmonary drug delivery 
due to their inherent mucoadhesive properties.27-28   Specifically, primary amines on chitosan 
oligosaccharides associate with the negatively charged sialic acid residues of mucins via 
electrostatic interactions.27,29-30  As drug delivery vehicles, mucoadhesive scaffolds increase the 
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retention time in the airways by preventing drug removal via coughing or particle mucociliary 
clearance.27,31  In fact, chitosan has already been incorporated into antibiotic-releasing particles to 
enhance pulmonary delivery.32-36 Alternatively, Klinger-Strobel et al. reported the development of 
non-mucoadhesive drug delivery scaffolds.31  Most commonly, polyethylene glycol (PEG) 
modifications have been used to create non-adhesive or “muco-inert” drug-releasing particles that 
exhibit improved particle penetration in human cervicovaginal mucus,37-38 bacterial biofilms,39 and 
CF sputum37-40 via the hydrophilicity and charge neutrality of the PEG moiety.  Herein, chitosan 
oligosaccharides with various mucoadhesive properties but similar NO storage and release 
properties were synthesized to investigate the role of scaffold mucoadhesion on the mucolytic 
efficacy of NO-releasing therapeutics. 
4.2 Materials and Methods 
4.2.1 Materials 
Medium molecular weight chitosan (viscosity 200-800 centipoise), 2-methylaziridine, 
ethyl acrylate, tert-butyl acrylate, sulfopropyl acrylate potassium salt, sodium dodecyl sulfate 
(SDS), dithiothreitol (DTT), bovine serum albumin (BSA), and type II gastric pig mucin (GPM) 
were purchased from Sigma-Aldrich (St. Louis, MO). Nitric oxide gas was purchased from Praxair 
(Sanford, NC).  Standardized NO (26.85 ppm, balance N2), Argon (Ar), and nitrogen (N2) gases 
were purchased from Airgas National Welders (Durham, NC).  Sodium methoxide was purchased 
from Acros Organics (Geel, Belgium).   
Tris-acetate-EDTA (TAE) buffer (10x) was purchased from Mediatech, Inc. (Manassas, 
VA) and diluted 1:10 in distilled water prior to use.  Saline-sodium citrate (SSC) buffer (20x) was 
purchased from Promega Corporation (Madison, WI) and diluted 1:5 to obtain 4x SSC buffer.  
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Dulbecco’s phosphate buffered saline (DPBS, 1x) was purchase from Life Technologies 
(Carlsbad, CA).  Powdered milk (Drink ‘n Mix) was purchased from Walmart (Durham, NC).  
Neutral buffered formalin (NBF, 10 vol.%) was purchased from Sigma Aldrich (St. Louis, MO).  
Phosphate buffer (10 mM, pH 6.5) was prepared in house using common laboratory salts and 
reagents.   
Anti-MUC5B antibody (H-300) was purchased from Santa Cruz Biotechnology (Dallas, 
TX).  Anti-MUC5AC antibody (45M1) was purchased from Abcam (Cambridge, MA).  Secondary 
antibodies (IRDye 800CW Donkey anti-Mouse IgG and IRDye 680RD Donkey anti-Rabbit IgG) 
were purchased from LI-COR Biosciences (Lincoln, NE).  4’,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) was purchased from Life Technologies (Carlsbad, CA). 
Distilled water was purified using a Millipore Milli-Q UV Gradient A-10 system (Bedford, 
MA).  All common laboratory salts and reagents were purchased from Fisher Scientific 
(Pittsburgh, PA).  All materials were used without further purification unless otherwise specified.    
Mucus was harvested from primary human bronchial epithelial (HBE) cell cultures as 
previously described.41  Briefly, primary cell cultures obtained from excess surgical tissue (UNC 
Chapel Hill Tissue Core Facility) were grown on 0.5 mm pore-sized Millicell cell culture inserts 
(Millipore, Bedford, MA) in air-liquid interface media (UNC Chapel Hill Tissue Core Facility) for 
a minimum of 6 weeks until the cultures developed cilia, and well-defined periciliary liquid (PCL) 
and mucus layers.   Mucins were harvested from one continuously grown primary cell culture at 
distinct time points and stored at 3 °C prior to use.  
Sputum samples were collected from CF patients by spontaneous expectoration.  All 
studied were approved by the UNC Chapel Hill Institutional Review Board with informed consent 
obtained from all subjects.  All samples were stored in sterile containers at 3 °C prior to use. 
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4.2.2 Synthesis of 2-methylaziridine modified chitosan oligosaccharides 
Polymeric chitosan was oxidatively degraded into chitosan oligosaccharides as previously 
described.42  Briefly, medium molecular weight chitosan (2.5 g) was dissolved in 15 wt. % 
hydrogen peroxide (50 mL) and stirred at 85 °C for 1 h.  Insoluble, non-degraded chitosan was 
removed by filtration.  Water-soluble oligosaccharides were collected via precipitation in acetone, 
washed copiously with ethanol, and dried in vacuo.  A Ubbelohde viscometer was used to measure 
the viscosity of the chitosan oligosaccharides in a solution of sodium chloride (0.20 M) and acetic 
acid (0.10 M) at 25 °C.  The molecular weight was calculated to be 4.410 ± 0.037 kD using the 
classic Mark-Houwink equation (η = 1.81 × 10-3 M0.93).43  
 The water-soluble chitosan oligosaccharides were then modified with 2-methylaziridine 
(Figure 4.1).  Chitosan oligosaccharides (0.50 g) were dissolved in water (10.00 mL).  While 
stirring, hydrochloric acid (12.1 M, 27.5 µL), water (250 µL), and 2-methylaziridine (178 µL, 1:1 
molar ratio to primary amines on the unmodified chitosan oligosaccharide) was added to the 
solution followed by stirring for 5 d at 25 °C and 24 h at 85 °C.  The resulting 2-methylaziridine-
modified chitosan oligosaccharides (COS) were precipitated in acetone, washed with methanol to 
remove excess 2-methylaziridine, and dried in vacuo.  
4.2.3 Acrylate modifications of chitosan oligosaccharides 
The mucoadhesive properties of COS were altered by the Michael addition of acrylates to 
the amino groups (Figure 4.1).    Ethyl acrylate (EA, 2.08 mL) and tert-butyl acrylate (TBuA, 2.78 
mL) were added to COS (500 mg) in a solution of water (6.00 mL), methanol (14.00 mL), 
ammonium hydroxide (1.00 mL).  Methanol was excluded from the reaction solvent for the 
addition of sulfopropyl acrylate (SPA) as it is water soluble.  Therefore, SPA (4.43 g) was added 
to COS (500 mg) in a solution of water (20.00 mL) and ammonium hydroxide (1.00 mL).  A  
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Figure 4.1 Chitosan oligosaccharide modification with 2-methylaziridine and subsequent 
functionalization with acrylates. 
+
+
R
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10-fold molar excess of acrylate (vs. primary amine) was used in all reactions to maximize the 
efficiency of the acrylate addition.  After 72 h, acrylate-modified COS was precipitated with 
acetone, collected via centrifugation, and washed with methanol to remove excess reagent.  As 
SPA is not soluble in methanol, this product was washed copiously with ethanol.  The resulting 
EA-, TBuA-, and SPA-modified COS (COS-EA, COS-TBuA, and COS-SPA, respectively) were 
dried in vacuo overnight and stored at room temperature.  Removal of unreacted acrylate was 
verified by the disappearance of the vinyl protons for the products in 1H NMR spectra.  
4.2.4 1H NMR characterization 
Acrylate-modified COS were characterized by 1H NMR to determine the degree of 
substitution and product purity.  Modified COS products (6.0 mg) were dissolved in D2O (600 
µL), followed by the collection of NMR spectra using a Bruker 400 MHz DRX spectrometer.  
Representative spectra with peak designations of COS, COS-EA, COS-TBuA, and COS-SPA are 
provided in Figures 4.2-4.5.  As described previously,44 the degree of substitution was determined 
from the peak area of δ 4.1 ppm (s, OCH2CH3 of EA), 1.3 ppm (br, OCC3H9 of TBuA), and 4.1 
ppm (s, OCH2CH2CH2SO3
- of SPA) against 4.4 ppm (s, OCH(CHNH2)O of COS) for COS-EA, 
COS-TBuA, and COS-SPA, respectively.  All calculations for the degree of substitution were the 
deacetylation level of the oligosaccharide backbone (85% as reported by manufacturer), as the N-
acetylglucosamine monomer (15%) does not facilitate modification.   
4.2.5 Synthesis of NO-releasing chitosan oligosaccharides 
To impart NO storage and release, N-diazeniumdiolate NO donors were formed on the 
secondary amines of the COS and acrylate-modified COS.42  Modified chitosan oligosaccharides 
(15 mg) were dissolved in a solution of water (300 µL), methanol (700 µL) and 5.4 M sodium  
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Figure 4.2 1H NMR Characterization of COS. 
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Figure 4.3 1H NMR Characterization of COS-EA.  The degree of substitution is 
characterized by integration of the peak X against peak A. 
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Figure 4.4 1H NMR Characterization of COS-TBuA.  The degree of substitution is 
characterized by integration of the peak X against peak A. 
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Figure 4.5 1H NMR Characterization of COS-SPA.  The degree of substitution is 
characterized by integration of the peak X against peak A. 
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methoxide (25 µL) in a 1 dram vial equipped with a stir bar.  The open vial was placed in a 160 
mL Parr general purpose stainless steel pressure vessel and stirred vigorously.  Oxygen was 
removed from the reaction vessel by purging with argon (10 s, 8 bar) thrice, followed by three 
longer argon purges (10 min, 8 bar).  The vessel was then filled with potassium hydroxide-purified 
NO gas (10 bar) for 72 h at room temperature.  Afterwards, the argon purging procedure was 
repeated to remove unreacted NO.  N-diazeniumdolate-modified chitosan oligosaccharides (COS-
NO, COS-EA-NO, COS-TBuA-NO, and COS-SPA-NO) were precipitated in acetone, collected 
via centrifugation to yield a yellow powder, dried in vacuo, and stored at -20 °C until use.  
4.2.6 Chemiluminescence detection of NO release 
A Sievers 280i Chemiluminescence Nitric Oxide Analyzer (Boulder, Colorado) was used 
to quantify NO release. Prior to analysis, the instrument was calibrated with air passed through a 
NO zero filter (0 ppm NO) and 26.8 ppm of NO standard gas (balance N2).  The N-
diazeniumdiolate modified chitosan oligosaccharides (1.0 mg) were immersed in 30 mL of 
deoxygenated PBS (pH 6.5) at 37 °C whereupon released NO was carried by N2 gas to the detector 
at a flow rate of 80 mL/min.  Additional N2 flow was supplied to the sample flask at 200 mL/min 
to match the collection rate of the instrument.  Analysis was terminated once NO concentrations 
fell below 10 ppb NO/mg COS-NO. 
4.2.7 Turbidimetric titrations of mucins 
Gastric pig mucin (960 mg) was dissolved in 250 mL of sterile phosphate buffer (PB) at 4 
°C for 18 h.  The mucin suspension was centrifuged (1,500 × g, 4 °C, 0.5 h) to remove insoluble 
components.  The resulting mucin solution was stored in sterile containers at 4 °C for up to 1 week 
prior to use.  Solutions of mucin and acrylate-modified chitosan oligosaccharides were prepared 
by combining 236 µL of the purified mucin solution with 34 µL of the chitosan oligosaccharide 
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solutions (3.6 - 54.5 mg/mL in sterile PB) in a 96-well plate.  The mucin and chitosan solutions 
were incubated for 1 h at 37 °C with gentle shaking (100 rpm) after which the absorbance was read 
at 540 nm using a Thermoscientific Multiskan EX plate reader.   Corrected absorbances were 
obtained after subtracting the absorbance of the chitosan oligosaccharides (i.e., without mucin) 
from the COS-mucin absorbance. 
4.2.8 Zeta potentials of mucin-chitosan oligosaccharide aggregates 
 Gastric pig mucin (10.0 mg) was dissolved in 10.00 mL sterile PB at 4 °C for 18 h.  The 
mucin suspension was centrifuged (1,500 × g, 4 °C, 0.5 h) to remove insoluble components.  The 
resulting mucin solution was stored in sterile containers at 4 °C for up to 1 week prior to use.  
Modified chitosan oligosaccharide solids were added to the mucin solution, vortexed until 
dissolved, and incubated for 1 h at 37 °C.  The zeta potential (i.e., surface charge) of the mucin-
chitosan aggregate was determined using a Malvern Zetasizer Nano-ZS equipped with a 10 mW 
HeNe laser (633nm) and a NIBS detector at an angle of 173°.   
4.2.9 Gel Electrophoresis  
 Concentrated stocks of chitosan oligosaccharides (COS and COS-SPA) and NO-releasing 
chitosan oligosaccharides (COS-NO and COS-SPA-NO) or DTT (20 µL) were added to HBE 
mucus (40 µL), stirred gently, and incubated at room temperature for 2 h with gentle rocking.  As 
CF sputum contains proteolytic enzymes, the incubation time was decreased to 1 h to reduce 
enzymatic degradation of the sample.   
Following treatment, samples (40 µL) were loaded onto a 0.7% agarose gel in 1x TAE 
buffer with 1% SDS for electrophoretic separation of MUC5AC and MUC5B at 80 V for 90 min.  
The gel was reduced with 10 mM DTT for 20 min.  Mucins were transferred by vacuum (45 mbar, 
1.5 h) in 4x SSC buffer onto a nitrocellulose membrane with a pore size of 45 µm (Optitran BA-S 
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85 membrane, GE Healthcare Life Sciences, Piscataway, NJ ).  Following blocking of nonspecific 
interactions with powdered milk (3 wt% in DPBS) for 1 h, mucins were detected by exposure to 
diluted primary antibodies raised against MUC5AC and MUC5B (0.1 µg/mL in 3% milk) 
overnight (3 °C).  The membranes were washed thrice with DPBS (10 min) and revealed with 
fluorescently labeled secondary antibodies (0.2 µg/mL in 3% milk, 1 h, 25 °C).  The gels were 
subsequently washed in DPBS again and were analyzed on a LI-COR Odyssey CLx Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE).  Migration distances were quantified using 
Image J (US National Institute of Health, Bethesda, MD).  For CF sputum samples, migration 
distances were normalized to the PBS-treated sample to account for the large degree of 
heterogeneity. 
4.2.10 Confocal microscopy 
 Prior to being loaded into the agarose gel, CF sputum samples (5µL) exposed to COS, 
COS-NO, COS-SPA, or COS-SPA-NO were carefully smeared on glass microscopy slides to 
prevent mechanical disruption of mucin and DNA network.  The samples were fixed with NBF 
(10 vol. %), washed with DPBS, and blocked with BSA (3 wt. % in DPBS) for 1 h at room 
temperature.    Mucins networks were visualized by immunohistochemical detection.  First, 
MUC5AC and MUC5B were identified via exposure to primary antibody solutions (0.4 and 0.2 
µg/mL for MUC5AC and MUC5B, respectively).  The slides were washed with DPBS three times 
(10 min) prior to exposure to secondary antibodies (1 µg/mL) and DAPI (5 µg/mL) for 1 h at 25 
°C to facilitate quantitative measurement.  The slides were then washed with DPBS (10 min) and 
mounted with Fluorsave.  Confocal images were obtained with an Olympus FV 1000 (Olympus, 
Hamilton, Bermuda) with a 20x objective. 
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4.2.11 Parallel plate rheology 
Spontaneously expectorated sputum from one CF patient collected at a single time point 
was used for rheological measurements.  Concentrated solutions of COS-NO (27.8 µL) were added 
to 250 µL aliquots of sputum to achieve final COS-NO concentrations of 0, 5, 10, and 20 mg/mL.  
Sputum samples were slowly rotated at room temperature for 1 h.  The rheological properties of 
the treated samples were measured via amplitude sweep experiments over a stress range of 0.025-
50 Pa at a single frequency (1 Hz) on a Bohlin Gemini Rheometer (Malvern Instruments, 
Worcestershire, UK) with a 20 mm diameter parallel plate set to a gap thickness of 50 mm.  
Rheological measurements were performed at 23 °C to minimize sample dehydration.  The elastic 
modulus (G’) and viscous modulus (G’’) were determined from the linear regimes as previously 
reported.45  All values are reported as the mean ± standard error of the mean (SEM) for a minimum 
of three separately evaluated aliquots of the treated sputum sample. 
4.2.12 Statistical analysis 
 All values are reported as the mean ± standard deviation for three or more pooled 
experiments unless otherwise noted.  Statistical significance was determined by two-tailed 
student’s t-test. 
4.3 Results and Discussion 
4.3.1  Synthesis of Mucoadhesive Chitosan Oligosaccharides 
To determine if mucoadhesion altered the mucolytic efficacy of NO-releasing chitosan 
oligosaccharides, 2-methylaziridine-modified chitosan oligosaccharides (COS) were modified 
with three structurally distinct acrylates (Figure 4.1).  These modifications were chosen to 
sterically block the primary amine on COS, as primary amines are the main source of chitosan’s 
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mucoadhesive properties.46  Reaction conditions for the Michael addition of acrylate moieties to 
the COS scaffold were optimized to maximize modification efficiency.   Specifically, the synthesis 
was carried out under basic conditions to increase primary amine nucleophilicity and reactivity 
towards the β-carbon of the acrylate vinyl group.  For example, the modification efficiency was 
10.8 ± 1.1% when the reaction between COS and TBuA was carried out under neutral conditions 
(pH 7) versus 71.5 ± 13.5 % at pH 12.   All reactions were carried out at room temperature as 
heating to 50 °C produced undesirable side-reactions between ethyl acrylate and the chitosan 
backbone (data not shown).  These optimized reaction conditions resulted in similar modification 
efficiencies of ~ 80% for all three acrylate moieties (Table 4.1).   
4.3.2 Nitric oxide-release properties   
 To impart NO storage and release, N-diazeniumdiolates were formed on the modified 
chitosan oligosaccharides via exposure to high pressures of NO gas.42  Nitric oxide storage was 
tuned by maintaining constant solvent ratios and base concentrations for all scaffolds.  
Modification of the COS scaffold acrylate did not alter NO payloads ([NO]total ~ 0.4 µmol/mg) or 
release kinetics (t1/2 ~ 30 min) regardless of the acrylate modification (Table 4.1).  While NO 
release from N-diazeniumdiolates may be altered by charge stabilization or hydrophobicity 
imparted from local functional groups,47 the data indicates that NO-release kinetics from acrylate-
modified chitosan oligosaccharides are primarily influenced by the hydrophobicity of the chitosan 
backbone.  Indeed, the NO-release kinetics of these materials were somewhat expected as the 
acrylate modifications did not significantly alter the hydrophobicity of the materials.   
4.3.3 Mucoadhesion of acrylate- and 2-methylaziridine-modified chitosan oligosaccharides 
  
140 
 
  
Table 4.1     Acrylate modification and NO-release characteristics of modified chitosan 
oligosaccharides in PBS (pH 6.5, 37 °C).  All values are reported as the mean ± standard deviation for 
3 or more pooled experiments. 
 
Degree of 
substitutiona  
(%) 
[NO]totalb 
(µmol/mg) 
[NO]maxc 
(ppb/mg) 
t(1/2)d 
(min) 
tde 
(h) 
COS — 0.44 ± 0.11 2800 ± 600 36.1 ± 2.8 7.85 ± 0.75 
COS-EA 76.3 ± 3.7 0.42 ± 0.16 3200 ± 1100 28.8 ± 5.2 7.62 ± 0.67 
COS-TBuA 71.5 ± 13.5 0.42 ± 0.09 2500 ± 400 25.3 ± 8.6 7.74 ± 0.74 
COS-SPA 90.6 ± 13.9 0.39 ± 0.12 3300 ± 1100 28.9 ± 4.3 6.72 ± 1.92 
a relative to primary amines, b Total NO, c Max NO Flux, d Half-life, e Duration of NO-release 
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Turbidimetric titrations of mucin with acrylate-modified COS were carried out to 
determine the mucoadhesion of the chitosan oligosaccharide scaffolds (Figure 4.6).  In the 
presence of mucoadhesive polymers, mucins form self-assembled complexes which scatter 
light.30,48  As such, the turbidity of mucin solutions (as measured by corrected absorbance) 
increases with the addition of mucoadhesive scaffolds but remains constant with muco-inert 
scaffolds.  Turbidity was monitored at 540 nm to maximize sensitivity towards mucin-chitosan 
complexes while minimizing the absorbance of free chitosan oligosaccharides in solution (λmax = 
375 nm). 
The turbidity of mucin solutions increased rapidly at low chitosan concentrations for all 
scaffolds tested with the exception of COS-SPA, demarcating it as the least mucoadhesive scaffold 
(Figure 4.6).   As electrostatic interactions between protonated amines on the chitosan scaffold and 
negatively charged residues on mucins are the primary cause of chitosan mucoadhesion,29-30,46 
electrostatic repulsion between mucins and the negatively charged sulfonate group of COS-SPA 
likely prevented the formation of chitosan-mucin aggregates.  While the TBuA and EA 
modifications sterically block amines on the COS scaffold, this steric hindrance did not 
significantly reduce mucoadhesion compared to the unmodified COS scaffold (Figure 4.6). 
 Zeta potential measurements of chitosan-mucin aggregates corroborated the findings from 
turbidimetric titrations (Figure 4.7).  At pH 6.5, GPM exhibited a zeta potential of 9.8 ± 0.5 mV.  
Adding positively charged chitosan oligosaccharides (i.e., COS, COS-TBuA, and COS-EA) to 
dilute mucin solutions increased the zeta potential, indicating the adherence of chitosan 
oligosaccharides to the mucins.  The change in zeta potential as a function of chitosan 
oligosaccharide concentration plateaued as the charge of the mucin was neutralized, verifying the 
electrostatic nature of the interactions.  Treatment with negatively charged COS-SPA did not  
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Figure 4.6 Turbidimetric titration of gastric pig mucin (GPM) with modified chitosan 
oligosaccharides.   
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Figure 4.7 Zeta potential measurements of GPM-chitosan aggregates formed upon the 
addition of chitosan oligosaccharides to mucin solutions (1 mg/mL in 10 mM PB, pH 6.5). 
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significantly alter the zeta potential at any of the tested concentrations, further supporting 
electrostatic repulsion between COS-SPA and mucin. 
4.3.4 Electrophoretic separation of purified mucus following treatment with chitosan 
oligosaccharides.  
To determine the effects of NO on mucin size (i.e., molecular weight), mucus collected 
from HBE cultures was treated with control (i.e., non-NO-releasing) and NO-releasing chitosan 
oligosaccharides and evaluated using gel electrophoresis (Figure 4.8).  The most and least 
mucoadhesive chitosan oligosaccharides (i.e., COS and COS-SPA, respectively) were compared 
to determine the importance of scaffold mucoadhesion.  Treatment with control scaffolds did not 
alter mucin migration compared to samples treated with PBS regardless of the mucoadhesive 
properties of the scaffold.  Retained mucin monomers were visible in mucus secretions treated 
with 10-20 mg/mL COS (Figure 4.8).  As shown in Figure 4.7, treatment with COS reduced the 
magnitude of the mucin zeta potential, which accounts for the decreased migration of the 
monomers in the applied electric field (Figure 4.8).  
 Treatment with COS-NO increased the migration of both MUC5AC and MUC5B during 
electrophoretic separation (Figure 4.9).  This increase in migration was statistically significant (p 
≤ 0.05) for both mucins at 10 mg/mL COS-NO.  As treatment with the COS scaffold did not alter 
migration, we are able to attribute this effect to NO.  While the polarity of NO on the COS scaffold 
may alter mucin electrophoretic mobility, the inability of the negatively charged COS-SPA 
scaffold to alter migration suggests that NO released from COS-NO reduced the size of mucin 
multimers, leading to faster migration. 
 Mucins from HBE mucus were also treated with DTT for comparison to the mucolytic 
properties of NO (Figure 4.10).  While DTT is too toxic for clinical use,49-50 it is commonly used  
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Figure 4.8 Representative western blot of Muc5AC mucins from HBE mucus treated with 
COS, COS-NO, COS-SPA, and COS-SPA-NO for 2 h at 25°C at concentrations ranging from 
0-20 mg/mL.  Similar trends were observed for Muc5B.   
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Figure 4.9 Migration distances of (A) Muc5AC and (B) Muc5B mucins in HBE Mucus 
following treatment with modified chitosan oligosaccharides for 1 h at room temperature.  The 
migration distances of mucin treated with an equal volume of PBS are denoted with dashed 
horizontal lines.  All values are presented as the mean ± standard deviation for 3 or more 
pooled experiments.  Asterisks (*) indicate significant differences (p < 0.1) relative to 
treatment with PBS.   
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for mucin reduction in in vitro assays and acts by cleaving mucin disulfide bonds.  Exposure to 
DTT at concentrations ≥ 5 mM fully reduced both MUC5AC and MUC5B mucins (Figure 4.10).  
Following DTT exposure, completely reduced MUC5AC and MUC5B migrated distances of 2.52 
± 0.02 and 1.30 ± 0.09 cm, respectively, while treatment with 20 mg/mL COS-NO resulted in 
migration distances of 2.52 ± 0.48 and 1.45 ± 0.35 cm, respectively.  The similarity between 
migration distances for both treatments demonstrates that treatment with 20 mg/mL COS-NO fully 
degraded both mucins, indicating its effectiveness as a mucolytic agent.  
As treatment with COS-SPA-NO did not alter the migration of MUC5AC or MUC5B, 
scaffold mucoadhesion was determined to be necessary for effective NO delivery (Figure 4.9).  
This conclusion is consistent with previous reports as association between NO-releasing scaffolds 
and drug targets leads to localized drug delivery and enhances therapeutic efficacy.25  In contrast, 
poor scaffold-target association results in distal NO release, thereby lowering any therapeutic 
activity.  For example, dendrimers51-53 and silica nanoparticles26,54-56 that associate with bacteria 
membranes improve the bacteria killing of the macromolecular NO release scaffolds compared to 
non-associating NO donors, suggesting that mucoadhesion would also advantageous in designing 
NO-releasing scaffolds to alter mucolytic activity. 
4.3.5 Electrophoretic separation of CF sputum following treatment with chitosan 
oligosaccharides 
While NO released from COS-NO altered mucin migration in HBE mucus, the complexity 
of CF sputum (e.g., high concentrations of DNA, proteins, bacteria, and neutrophils) may influence 
NO delivery and action.  We thus evaluated the effects of COS, COS-NO, COS-SPA, and COS-
SPA-NO on  mucins in CF sputum using gel electrophoresis (Figure 4.11).  As with HBE mucus, 
treatment with controls (i.e., non-NO-releasing chitosan oligosaccharides) did not affect mucin  
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Figure 4.10 Representative western blot of HBE mucus treated with DTT for 10 min at 
room temperature.  This figure was generously provided by Prof. Camille Ehre of the Marsico 
Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC (unpublished 
data).    
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migration.  In contrast, mucin migration was enhanced relative to controls following treatment 
with COS-NO at concentrations ≤ 10 mg/mL for both MUC5AC and MUC5B (Figure 4.12), 
further indicating  the mucolytic activity of this scaffold.  While it has been argued that muco-inert 
scaffolds are more effective for drug delivery in CF airways due to improved penetration,31 
treatment with COS-SPA-NO failed to influence mucin migration.  In both HBE mucus and CF 
sputum, the mucolytic activity of NO-releasing chitosan oligosaccharides was thus dependent 
upon the mucoadhesive properties of the scaffold.  
4.3.6 Fluorescent microscopy of CF sputum 
 To visualize NO-mediated changes in the network formed by mucins and DNA in CF 
sputum, samples imaged with a confocal laser scanning microscope (Figure 4.13).  As expected, 
networks of MUC5AC (red) and MUC5B (green) intertwined to form three-dimensional 
architectures characterized by thick filaments of mucins and web-like mucin sheets in the PBS-
treated sample.   Intact neutrophils (blue) were embedded within the three-dimensional mucin 
network.  Treatment with the chitosan oligosaccharides at 20 mg/mL caused neutrophil apoptosis, 
regardless of the chitosan composition, as evidenced by the increase in extracellular DNA (Figure 
4.13).  Chitosan oligosaccharide-induced neutrophil apoptosis is proposed to be responsible for 
the anti-inflammatory properties of this scaffold.57-58  Treatment with COS-SPA and COS-SPA-
NO had no other discernable effects on the CF sputum architecture.  
 Both COS and COS-NO, the positively charged chitosan variant, significantly altered the 
appearance of the mucin networks in CF sputum.  While the filaments and webs of the elastic 
network were still visible, treatment with COS induced aggregation of the mucin networks as was 
apparent by the increased fluorescence (i.e., brightness) of the images.  Additionally, the presence 
of large sheets of flowing mucin was decreased in sputum treated with COS.  These images show  
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Figure 4.11 Representative western blot of MUC5AC mucins from CF sputum treated with 
COS, COS-NO, COS-SPA, and COS-SPA-NO for 1 h at 25°C at concentrations ranging from 
0-20 mg/mL.  Similar trends were observed for MUC5B. 
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Figure 4.12 Relative migration distances of (A) MUC5AC and (B) MUC5B mucins 
from CF sputum following treatment with modified chitosan oligosaccharides for 1 h at 
room temperature.  Migration distances were normalized to CF sputum samples treated 
with an equal volume of PBS.  All values are presented as the mean ± standard deviation 
for n=3 or more pooled experiments.  Asterisks (*) indicate significant differences (p < 
0.1) relative to treatment with PBS. 
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Figure 4.13 Confocal microscopy images of CF sputum treated with PBS (A-D)or 20 
mg/mL COS (E-H), COS-NO (I-L), COS-SPA (M-P), or COS-SPA-NO (Q-T) for 1 h at 
25 °C. 
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that COS-mucin aggregation persists even in the complex viscoelastic CF sputum network.   In 
contrast to treatment with COS alone, COS-NO greatly degraded the mucin network.  Following 
treatment, the length of mucin filaments was decreased and the mucin network appeared relaxed 
with no dimensionality (Figure 4.13).  As the presence of highly intertwined mucin structures 
correlate with sputum elasticity,59 the NO-mediated disruption of this network suggests NO’s 
ability to reduce sputum elasticity. 
4.3.7 CF sputum rheology 
 The ultimate test of a mucolytic agent is its ability to decrease mucus viscosity and 
elasticity, as these rheological parameters are the predominant predictors of mucociliary and 
coughing clearance.7,60-61  Due to superior efficacy in vitro, COS-NO was chosen for rheological 
analysis.   Dose-dependent reductions in sputum viscosity and elasticity were observed following 
treatment with COS-NO for 1 h at room temperature (Figure 4.14).  At the lowest concentration 
tested (5 mg/mL), COS-NO reduced sputum elasticity by 74.5% and viscosity by 66.4 % compared 
to PBS-treated controls while treatment with 20 mg/mL reduced sputum elasticity and viscosity 
by an order of magnitude.    
While it is difficult to compare rheological data across literature reports due to the diversity 
of exposure conditions and measurement parameters,62 treatment with COS-NO produced similar 
changes in sputum viscoelasticity as conventional therapeutics.   For example, Seagrave et al. 
reported that NAC treatment for 24 h decreased the viscosity and elasticity of HBE mucus by an 
order of magnitude versus controls.45  Similarly, Shah et al. observed reduced sputum viscosity 
and elasticity by 59% and 68%, respectively, following treatment with dornase alfa for 10 min.13  
While the concentration of COS-NO required to alter sputum rheological properties is greater than  
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Figure 4.14 (A) Elastic and (B) viscous moduli of CF sputum following treatment with 
COS-NO for 1 h at 25 °C.  Values presented as the mean ± standard error of the mean for n=3 
triplicate measurements. 
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the NAC and dornase alfa used in these reports, longer exposure conditions and/or greater NO 
payloads would decrease the required dose.  The development of mucoadhesive NO-releasing 
chitosan oligosaccharides with improved NO payloads for enhanced mucolytic efficacy is 
currently underway in our laboratory. 
4.4 Conclusions 
 The antibacterial properties of NO-releasing scaffolds are well documented,25,63-64 however 
the utility of such materials as mucolytic agents is just beginning to be developed.  The work 
reported herein sought to determine the biophysical effects of NO released from N-
diazeniumdiolate-modified chitosan oligosaccharides on HBE mucus and CF sputum as well as 
the importance of mucoadhesion in effective drug delivery.  Mucoadhesive COS-NO increased 
mucin migration during electrophoresis in both HBE mucus and CF sputum by reducing the 
molecular weight of multimeric mucin.  Control chitosan oligosaccharides did not alter mucin 
migration, indicating that NO is the only mucoactive agent.   In addition to decreasing the 
molecular weight of mucins, the NO released from COS-NO is capable of destroying the mucin 
network of CF sputum.  Confocal microscopy of CF sputum treated with COS-NO revealed 
substantial alterations in the mucin networks, including decreased length of mucin fibers and the 
loss of three-dimensional structures.   
 Both the reduction in mucin size and the destruction of the three-dimensional mucin 
network by NO ultimately decreases the viscoelasticity of CF sputum.   While the diminished 
elastic and viscous moduli of CF sputum could be attributed to alterations in the DNA network via 
NO-mediated DNA cleavage, electrophoretic separations and confocal microscopy indicate that 
NO actively alters the mucin network.  Due to the poor clinical efficacy of NAC and an undesirable 
inflammatory response associated with DTT treatment, NO holds unique potential as a 
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combination antibacterial and mucolytic agent.  As such, NO-based therapies could also prove 
complimentary to dornase alfa treatments as dornase alfa only alters the DNA network of CF 
mucus. 
 While inhalation of NO gas has been proposed as a mucolytic therapy, our work indicates 
that NO released from mucoadhesive scaffolds may be more effective my improving NO delivery 
in CF mucus.  In all experiments, the mucoadhesive properties of the chitosan oligosaccharide 
scaffolds greatly influenced NO’s action.  As has been previously demonstrated in with other NO-
release vehicles and applications,25 the ability to localize NO delivery in CF mucus would likely 
improve the efficacy of NO treatment compared to NO gas while simultaneously improving the 
convenience of treatment and overall clinical utility.   
157 
 
REFERENCES 
Uncategorized References 
1. Button, B.; Cai, L.-H.; Ehre, C.; Kesimer, M.; Hill, D. B.; Sheehan, J. K.; Boucher, R. C.; 
Rubinstein, M. "A periciliary brush promotes the lung health by separating the mucus layer from 
airway epithelia." Science 2012, 337 (6097), 937-941. 
 
2. Boucher, R. "New concepts of the pathogenesis of cystic fibrosis lung disease." European 
Respiratory Journal 2004, 23 (1), 146-158. 
 
3. Matsui, H.; Wagner, V. E.; Hill, D. B.; Schwab, U. E.; Rogers, T. D.; Button, B.; Taylor, 
R. M.; Superfine, R.; Rubinstein, M.; Iglewski, B. H. "A physical linkage between cystic fibrosis 
airway surface dehydration and Pseudomonas aeruginosa biofilms." Proceedings of the National 
Academy of Sciences 2006, 103 (48), 18131-18136. 
 
4. Henke, M. O.; Ratjen, F. "Mucolytics in cystic fibrosis." Paediatric Respiratory Reviews 
2007, 8 (1), 24-29. 
 
5. Perez-Vilar, J.; Boucher, R. C. "Reevaluating gel-forming mucins' roles in cystic fibrosis 
lung disease." Free Radical Biology and Medicine 2004, 37 (10), 1564-1577. 
 
6. Yuta, A.; Baraniuk, J. N. "Therapeutic approaches to mucus hypersecretion." Current 
Allergy and Asthma Reports 2005, 5 (3), 243-251. 
 
7. Dippy, J.; Davis, S. "Rheological assessment of mucolytic agents on sputum of chronic 
bronchitics." Thorax 1969, 24 (6), 707-713. 
 
8. Sheffner, A.; Medler, E.; Jacobs, L.; Sarett, H. "The in vitro reduction in viscosity of human 
tracheobronchial secretions by acetylcysteine." American Review of Respiratory Disease 1964, 90, 
721-729. 
 
9. Rhee, C.-S.; Majima, Y.; Cho, J.-S.; Arima, S.; Min, Y.-G.; Sakakura, Y. "Effects of 
mucokinetic drugs on rheological properties of reconstituted human nasal mucus." Archives of 
Otolaryngology–Head & Neck Surgery 1999, 125 (1), 101-105. 
 
10. Tomkiewicz, R.; App, E.; De Sanctis, G.; Coffiner, M.; Maes, P.; Rubin, B.; King, M. "A 
comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway 
epithelial function and mucus changes in dog." Pulmonary Pharmacology 1995, 8 (6), 259-265. 
158 
 
 
11. Decramer, M.; Rutten-van Mölken, M.; Dekhuijzen, P. R.; Troosters, T.; van Herwaarden, 
C.; Pellegrino, R.; van Schayck, C. O.; Olivieri, D.; Del Donno, M.; De Backer, W. "Effects of N-
acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on 
NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial." The Lancet 2005, 
365 (9470), 1552-1560. 
 
12. King, M.; Dasgupta, B.; Tomkiewicz, R. P.; Brown, N. E. "Rheology of cystic fibrosis 
sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant 
human deoxyribonuclease I." American Journal of Respiratory and Critical Care Medicine 1997, 
156 (1), 173-177. 
 
13. Shah, P. L.; Scott, S. F.; Knight, R. A.; Marriott, C.; Ranasinha, C.; Hodson, M. E. "In vivo 
effects of recombinant human DNase I on sputum in patients with cystic fibrosis." Thorax 1996, 
51 (2), 119-125. 
 
14. Dawson, M.; Wirtz, D.; Hanes, J. "Enhanced viscoelasticity of human cystic fibrotic 
sputum correlates with increasing microheterogeneity in particle transport." Journal of Biological 
Chemistry 2003, 278 (50), 50393-50401. 
 
15. Fuchs, H. J.; Borowitz, D. S.; Christiansen, D. H.; Morris, E. M.; Nash, M. L.; Ramsey, B. 
W.; Rosenstein, B. J.; Smith, A. L.; Wohl, M. E. "Effect of aerosolized recombinant human DNase 
on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic 
fibrosis." New England Journal of Medicine 1994, 331 (10), 637-642. 
 
16. McCoy, K.; Hamilton, S.; Johnson, C. "Effects of 12-week administration of dornase alfa 
in patients with advanced cystic fibrosis lung disease." CHEST Journal 1996, 110 (4), 889-895. 
 
17. Quan, J. M.; Tiddens, H. A.; Sy, J. P.; McKenzie, S. G.; Montgomery, M. D.; Robinson, 
P. J.; Wohl, M. E. B.; Konstan, M. W.; Group, P. E. I. T. S. "A two-year randomized, placebo-
controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function 
abnormalities." Journal of Pediatrics 2001, 139 (6), 813-820. 
 
18. Syed, B. A.; Hamad, B. "The cystic fibrosis drug market." Nature Reviews Drug Discovery 
2014, 13 (10), 721-722. 
 
19. Miller, C. C.; Hole, D. R.; Murray, B. R.; Perry, B. Use of inhaled gaseous nitric oxide as 
a mucolytic agent or expectorant. US Patent 8518457 B2, Aug 27, 2013, 2013. 
 
159 
 
20. Tsutsumi, N.; Itoh, T.; Ohsawa, A. "Cleavage of SS bond by nitric oxide (NO) in the 
presence of oxygen: A disproportionation reaction of two disulfides." Chemical and 
Pharmaceutical Bulletin (Tokyo) 2000, 48 (10), 1524-1528. 
 
21. Duan, J.; Kasper, D. L. "Oxidative depolymerization of polysaccharides by reactive 
oxygen/nitrogen species." Glycobiology 2011, 21 (4), 401-409. 
 
22. Burney, S.; Caulfield, J. L.; Niles, J. C.; Wishnok, J. S.; Tannenbaum, S. R. "The chemistry 
of DNA damage from nitric oxide and peroxynitrite." Mutation Research: Fundamental and 
Molecular Mechanisms of Mutagenesis 1999, 424 (1), 37-49. 
 
23. Tamir, S.; Burney, S.; Tannenbaum, S. R. "DNA damage by nitric oxide." Chemical 
Research in Toxicology 1996, 9 (5), 821-827. 
 
24. Backlund, C. J. Nitric Oxide-Release Vehicles as Oral Disease Therapeutics. PhD. 
Dissertation, University of North Carolina at Chapel Hill, 2014. 
 
25. Carpenter, A. W.; Schoenfisch, M. H. "Nitric oxide release: Part II. Therapeutic 
applications." Chemical Society Reviews 2012, 41 (10), 3742-3752. 
 
26. Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; Holmuhamedov, 
E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-releasing silica nanoparticles." ACS 
Nano 2008, 2 (2), 235-246. 
 
27. Grenha, A.; Al-Qadi, S.; Seijo, B.; Remuñán-López, C. "The potential of chitosan for 
pulmonary drug delivery." Journal of Drug Delivery Science and Technology 2010, 20 (1), 33-43. 
 
28. Dash, M.; Chiellini, F.; Ottenbrite, R. M.; Chiellini, E. "Chitosan—a versatile semi-
synthetic polymer in biomedical applications." Progress in Polymer Science 2011, 36 (8), 981-
1014. 
 
29. Menchicchi, B.; Fuenzalida, J. P.; Bobbili, K. B.; Hensel, A.; Swamy, M. J.; Goycoolea, 
F. M. "Structure of chitosan determines its interactions with mucin." Biomacromolecules 2014, 15 
(10), 3550-3558. 
 
30. Sogias, I. A.; Williams, A. C.; Khutoryanskiy, V. V. "Why is chitosan mucoadhesive?" 
Biomacromolecules 2008, 9 (7), 1837-1842. 
 
160 
 
31. Klinger-Strobel, M.; Lautenschläger, C.; Fischer, D.; Pletz, M. W.; Mainz, J. G.; Bruns, 
T.; Tuchscherr, L.; Makarewicz, O. "Aspects of pulmonary drug delivery strategies for infections 
in cystic fibrosis-Where do we stand?" Expert Opinion on Drug Delivery 2015,  (0), 1-24. 
 
32. Manca, M.-L.; Mourtas, S.; Dracopoulos, V.; Fadda, A. M.; Antimisiaris, S. G. "PLGA, 
chitosan or chitosan-coated PLGA microparticles for alveolar delivery?: A comparative study of 
particle stability during nebulization." Colloids and Surfaces B: Biointerfaces 2008, 62 (2), 220-
231. 
 
33. Park, J.-H.; Jin, H.-E.; Kim, D.-D.; Chung, S.-J.; Shim, W.-S.; Shim, C.-K. "Chitosan 
microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation." 
International Journal of Pharmaceutics 2013, 441 (1), 562-569. 
 
34. Jain, D.; Banerjee, R. "Comparison of ciprofloxacin hydrochloride‐loaded protein, lipid, 
and chitosan nanoparticles for drug delivery." Journal of Biomedical Materials Research Part B: 
Applied Biomaterials 2008, 86 (1), 105-112. 
 
35. Osman, R.; Kan, P. L.; Awad, G.; Mortada, N.; Abd-Elhameed, E.-S.; Alpar, O. "Spray 
dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity." 
International Journal of Pharmaceutics 2013, 449 (1), 44-58. 
 
36. Ungaro, F.; d'Angelo, I.; Coletta, C.; di Villa Bianca, R. d. E.; Sorrentino, R.; Perfetto, B.; 
Tufano, M. A.; Miro, A.; La Rotonda, M. I.; Quaglia, F. "Dry powders based on PLGA 
nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, 
release rate and lung deposition pattern by hydrophilic polymers." Journal of Controlled Release 
2012, 157 (1), 149-159. 
 
37. Suk, J. S.; Lai, S. K.; Boylan, N. J.; Dawson, M. R.; Boyle, M. P.; Hanes, J. "Rapid 
transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine." 
Nanomedicine 2011, 6 (2), 365-375. 
 
38. Tang, B. C.; Dawson, M.; Lai, S. K.; Wang, Y.-Y.; Suk, J. S.; Yang, M.; Zeitlin, P.; Boyle, 
M. P.; Fu, J.; Hanes, J. "Biodegradable polymer nanoparticles that rapidly penetrate the human 
mucus barrier." Proceedings of the National Academy of Sciences 2009, 106 (46), 19268-19273. 
 
39. Forier, K.; Messiaen, A.-S.; Raemdonck, K.; Deschout, H.; Rejman, J.; De Baets, F.; Nelis, 
H.; De Smedt, S. C.; Demeester, J.; Coenye, T. "Transport of nanoparticles in cystic fibrosis 
sputum and bacterial biofilms by single-particle tracking microscopy." Nanomedicine 2013, 8 (6), 
935-949. 
161 
 
40. Suk, J. S.; Lai, S. K.; Wang, Y.-Y.; Ensign, L. M.; Zeitlin, P. L.; Boyle, M. P.; Hanes, J. 
"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-
adhesive polymer nanoparticles." Biomaterials 2009, 30 (13), 2591-2597. 
 
41. Hill, D. B.; Button, B. "Establishment of respiratory air–liquid interface cultures and their 
use in studying mucin production, secretion, and function." In Mucins, Springer: 2012; pp 245-
258. 
 
42. Lu, Y.; Slomberg, D. L.; Schoenfisch, M. H. "Nitric oxide-releasing chitosan 
oligosaccharides as antibacterial agents." Biomaterials 2014, 35 (5), 1716-1724. 
 
43. Maghami, G. G.; Roberts, G. A. "Evaluation of the viscometric constants for chitosan." 
Die Makromolekulare Chemie 1988, 189 (1), 195-200. 
 
44. Sashiwa, H.; Kawasaki, N.; Nakayama, A.; Muraki, E.; Yajima, H.; Yamamori, N.; 
Ichinose, Y.; Sunamoto, J.; Aiba, S.-i. "Chemical modification of chitosan. Part 15: Synthesis of 
novel chitosan derivatives by substitution of hydrophilic amine using N-carboxyethylchitosan 
ethyl ester as an intermediate." Carbohydrate Research 2003, 338 (6), 557-561. 
 
45. Seagrave, J.; Albrecht, H. H.; Hill, D. B.; Rogers, D. F.; Solomon, G. "Effects of 
guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary 
differentiated human tracheal-bronchial cells." Respiratory Research 2012, 13, 98. 
 
46. Khutoryanskiy, V. V. "Advances in mucoadhesion and mucoadhesive polymers." 
Macromolecular Bioscience 2011, 11 (6), 748-764. 
 
47. Riccio, D. A.; Schoenfisch, M. H. "Nitric oxide release: part I. Macromolecular scaffolds." 
Chemical Society Reviews 2012, 41 (10), 3731-3741. 
 
48. Rossi, S.; Ferrari, F.; Bonferoni, M. C.; Caramella, C. "Characterization of chitosan 
hydrochloride–mucin interaction by means of viscosimetric and turbidimetric measurements." 
European Journal of Pharmaceutical Sciences 2000, 10 (4), 251-257. 
 
49. Li, B.; Yi, P.; Zhang, B.; Xu, C.; Liu, Q.; Pi, Z.; Xu, X.; Chevet, E.; Liu, J. "Differences in 
endoplasmic reticulum stress signalling kinetics determine cell survival outcome through 
activation of MKP-1." Cellular Signalling 2011, 23 (1), 35-45. 
 
162 
 
50. Kachur, A. V.; Held, K. D.; Koch, C. J.; Biaglow, J. E. "Mechanism of production of 
hydroxyl radicals in the copper-catalyzed oxidation of dithiothreitol." Radiation Research 1997, 
147 (4), 409-415. 
 
51. Lu, Y.; Slomberg, D. L.; Shah, A.; Schoenfisch, M. H. "Nitric oxide-releasing amphiphilic 
poly (amidoamine) (PAMAM) dendrimers as antibacterial agents." Biomacromolecules 2013, 14 
(10), 3589-3598. 
 
52. Sun, B.; Slomberg, D. L.; Chudasama, S. L.; Lu, Y.; Schoenfisch, M. H. "Nitric oxide-
releasing dendrimers as antibacterial agents." Biomacromolecules 2012, 13 (10), 3343-3354. 
 
53. Worley, B. V.; Schilly, K. M.; Schoenfisch, M. H. "Anti-biofilm efficacy of dual-action 
nitric oxide-releasing alkyl chain modified poly(amidoamine) dendrimers." Molecular 
Pharmaceutics 2015, 12 (5), 1573-1583. 
 
54. Carpenter, A. W.; Slomberg, D. L.; Rao, K. S.; Schoenfisch, M. H. "Influence of scaffold 
size on bactericidal activity of nitric oxide-releasing silica nanoparticles." ACS Nano 2011, 5 (9), 
7235-7244. 
 
55. Slomberg, D. L.; Lu, Y.; Broadnax, A. D.; Hunter, R. A.; Carpenter, A. W.; Schoenfisch, 
M. H. "Role of size and shape on biofilm eradication for nitric oxide-releasing silica 
nanoparticles." ACS Applied Materials & Interfaces 2013, 5 (19), 9322-9329. 
 
56. Carpenter, A. W.; Worley, B. V.; Slomberg, D. L.; Schoenfisch, M. H. "Dual action 
antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica 
nanoparticles." Biomacromolecules 2012, 13 (10), 3334-3342. 
 
57. Dou, J.; Xu, Q.; Tan, C.; Wang, W.; Du, Y.; Bai, X.; Ma, X. "Effects of chitosan 
oligosaccharides on neutrophils from glycogen-induced peritonitis mice model." Carbohydrate 
Polymers 2009, 75 (1), 119-124. 
 
58. Yoon, H. J.; Moon, M. E.; Park, H. S.; Im, S. Y.; Kim, Y. H. "Chitosan oligosaccharide 
(COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells." Biochemical 
and Biophysical Research Communications 2007, 358 (3), 954-959. 
 
59. Hassett, D. J.; Cuppoletti, J.; Trapnell, B.; Lymar, S. V.; Rowe, J. J.; Sun Yoon, S.; Hilliard, 
G. M.; Parvatiyar, K.; Kamani, M. C.; Wozniak, D. J. "Anaerobic metabolism and quorum sensing 
by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: Rethinking 
163 
 
antibiotic treatment strategies and drug targets." Advanced Drug Delivery Reviews 2002, 54 (11), 
1425-1443. 
 
60. Dulfano, M.; Adler, K. "Physical properties of sputum: VII. Rheologic properties and 
mucociliary transport 1." American Review of Respiratory Disease 1975, 112 (3), 341-347. 
 
61. King, M.; Rubin, B. K. "Pharmacological approaches to discovery and development of new 
mucolytic agents." Advanced Drug Delivery Reviews 2002, 54 (11), 1475-1490. 
 
62. Lai, S. K.; Wang, Y.-Y.; Wirtz, D.; Hanes, J. "Micro-and macrorheology of mucus." 
Advanced Drug Delivery Reviews 2009, 61 (2), 86-100. 
 
63. Jones, M. L.; Ganopolsky, J. G.; Labbé, A.; Wahl, C.; Prakash, S. "Antimicrobial 
properties of nitric oxide and its application in antimicrobial formulations and medical devices." 
Applied Microbiology and Biotechnology 2010, 88 (2), 401-407. 
 
64. Seabra, A. B.; Justo, G. Z.; Haddad, P. S. "State of the art, challenges and perspectives in 
the design of nitric oxide-releasing polymeric nanomaterials for biomedical applications." 
Biotechnology Advances 2015, In Press. 
 
 
164 
 
 
CHAPTER 5:  SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary  
 The preceding chapters have examined the utility of NO-releasing chitosan 
oligosaccharides as potential CF therapeutics.  In Chapter 1, the pathogenesis of CF disease was 
described as a cascade of biophysical processes.  Inherited defects in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene cause sodium hyperabsorption and depletion 
of the periciliary layer (PCL).1  Without a hydrated PCL, mucociliary clearance fails with the 
accumulation of highly viscoelastic mucus layer.1  The physical properties of the CF mucus layer 
decrease the ability to eliminate pathogens while fostering the development of highly pathogenic 
and drug resistant infections.2  These chronic infections elicit a strong immune response, leading 
to lung disease and degradation.3  The NO-releasing chitosan oligosaccharides are proposed as a 
therapeutic treatment to potentially both eradicate bacteria biofilms and alter the biophysical 
properties of the CF mucus layer.  N-diazeniumdiolate-NO-donor modified chitosan 
oligosaccharides were chosen as the NO-release scaffold for study due to their low toxicity, ease 
of functionalization, mucoadhesive properties, biodegradability, and large NO payloads.   
 In Chapter 2, the bactericidal efficacy of NO-releasing chitosan oligosaccharides was 
determined under in vitro conditions that simulate CF airways.   As reactions between oxygen 
and NO produce several reactive species that enhance NO’s bactericidal action,4-6 it was 
hypothesized that NO may be less effective under the low oxygen conditions common to CF 
mucus.7-8  Importantly, such behavior was not observed.  Rather NO released from chitosan 
oligosaccharides was equally effective at inhibiting growth and eradicating planktonic P. 
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aeruginosa under aerobic and anaerobic conditions, indicating that the efficacy of NO would not 
be reduced in the CF airways.  Furthermore, the NO treatment was 10-fold more effective at 
eradicating P. aeruginosa biofilms under anaerobic conditions than tobramycin.  As the low 
oxygen conditions of the CF mucus layer curtail the effectiveness of traditional antibiotics,9-12 
the enhanced anti-biofilm activity of NO in these environments make it attractive as a therapeutic 
for treating bacterial infections in CF airways. 
 In Chapter 3, the effects of NO-releasing chitosan oligosaccharide treatment on the 
physical properties of P. aeruginosa biofilms were determined using multiple particle tracking 
microrheology.  Unlike tobramycin, which is only capable of eradication and not dispersal, NO-
releasing chitosan oligosaccharides were capable of both killing and physically degrading P. 
aeruginosa biofilms.   Treatment with NO-releasing chitosan oligosaccharides resulted in the 
destruction of biofilm segments, rather than only loosening the biofilms.  Of note, the chitosan 
oligosaccharide scaffold alone increased biofilm elasticity, caused physical contraction of the 
biofilm, and ostensibly mitigated the destructive power of NO.  Despite the negative effects of 
the scaffold, NO was capable of fluidizing P. aeruginosa biofilms, thus likely decreasing the 
contributions of P. aeruginosa biofilms to CF mucus viscoelasticity. 
 The effects of NO-releasing chitosan oligosaccharides on the physical properties of 
mucins from human bronchial epithelial cells and CF sputum were determined as a function of 
scaffold mucoadhesion in Chapter 4.  For each assay, NO that was released from non-
mucoadhesive scaffolds had no effect on the mucin networks.  In contrast, NO released from a 
mucoadhesive scaffold (COS-NO) both decreased mucin molecular weight and degraded mucin 
networks in CF sputum.  Destruction of the sputum network ultimately reduced the viscous and 
elastic moduli of CF sputum as determined by parallel plate rheology.  Collectively, the work in 
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my thesis demonstrates the potential utility of NO as a dual-action therapeutic as NO is capable 
of both bacterial biofilm eradication and mucolysis. 
5.2 Future Directions 
 While the antibacterial effects of NO-releasing chitosan oligosaccharides have been 
reported previously,13-14 my work is the first to characterize the biophysical activity of NO 
released from macromolecular scaffolds.  Nitric oxide was determined to decrease the 
viscoelastic properties of both bacterial biofilms and CF sputum.  These results are preliminary 
and further research is required to characterize the interactions between NO-releasing chitosan 
oligosaccharides and CF airways. 
5.2.1 In vitro cytotoxicity testing 
 The inherently low toxicity of chitosan makes it an attractive scaffold for pulmonary 
delivery.15  In previous work, NO-releasing chitosan oligosaccharides were capable of 
eradicating P. aeruginosa biofilms grown in a Center for Disease Control bioreactor at 
concentrations that were non-toxic to L929 mouse fibroblast cells.14 While L929 mouse 
fibroblast cells are widely used to assess the cytotoxicity of NO-releasing materials,13-14,16-20 this 
cell line does not accurately model CF airways.  Therefore, cytotoxicity assays should be 
performed using human bronchial epithelial (HBE) cell cultures in mucus.  The mucoadhesive 
properties of the chitosan oligosaccharides will likely determine how much NO is delivered to 
the epethilum in vivo.  Highly mucoadhesive scaffolds may not effectively penetrate the CF 
mucus barrier, resulting in NO release only at the mucus surface.15,21-22 In order to determine the 
validity of this hypothesis, cytotoxicity assays using NO-releasing chitosan oligosaccharides 
with a range of mucoadhesive properties should be examined.   
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Ideally, HBE cultures should be grown under conditions that would allow them to 
differentiate, form cilia, and secrete their own mucus layer.23  Unfortunately, the expense of this 
cell culture technique is prohibitive for determining the half maximal inhibitory concentrations 
(IC50) of multiple NO-releasing chitosan oligosaccharide scaffolds.  In order to study the 
protective properties of the mucus layer, mucus harvested from larger HBE cultures can be 
added to the cells in high throughput assays performed in 96-well plates.  Following treatment 
with chitosan oligosaccharides, cell viability could be determined using 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, a reagent that forms a 
colored product in the presence of active mitochondria (i.e., MTS assay).14,19-20  
5.2.2 Combined mucolytic and bactericidal efficacy of nitric oxide-releasing chitosan 
oligosaccharides 
 While the anti-biofilm action of NO-releasing chitosan oligosaccharides in CF relevant 
conditions was determined in Chapter 2, the effects of mucoadhesion on bactericidal properties 
remains unknown.  Ideal chitosan oligosaccharides should penetrate both CF mucus and bacterial 
biofilms to effectively deliver bactericidal concentrations of NO.  As such, the mucoadhesive 
properties of NO-releasing chitosan oligosaccharides may significantly alter the antibacterial 
activity in vivo. 
 Biofilm exopolysaccharide (EPS) matrix and CF mucus are highly complex and 
heterogeneous, but both can be generalized as intertwining networks of polyanionic polymers 
with large hydrophobic domains.24-26  As such, altering the cationic amines of chitosan 
oligosaccharides with negatively charged or hydrophilic groups will likely decrease association 
with biofilm EPS and the mucus network.  Therefore, chitosan oligosaccharides modified with 2-
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methylaziridine (COS), sulfopropyl acrylate (COS-SPA), PEG (COS-PEG), and thiols (COS-
SH) should be evaluated using similar bacterial assay formats. 
In order to determine the mucolytic and bactericidal efficacy NO-releasing chitosan 
oligosaccharides, multiple particle tracking rheology and minimum bactericidal concentration 
assays should be employed concurrently.  Growing P. aeruginosa biofilms in HBE mucus 
supplemented with fluorescent tracer particles accurately mimics in vivo growth conditions and 
allows for the rheological characterization of both biofilms and mucus.   In order to differentiate 
between the biofilms and mucus, P. aeruginosa biofilms should be grown with bacteria that 
express green fluorescent protein (GFP).  Samples treated with chitosan oligosaccharides can be 
aliquoted for simultaneous rheological and bactericidal assays since both methodologies require 
small sample volumes (i.e. ≤ 10 µL). 
5.2.3 Susceptibility of other CF pathogens to nitric oxide-releasing chitosan oligosaccharides 
 While P. aeruginosa is the most clinically relevant CF pathogen due to its association 
with patient morbidity and mortality,27 pulmonary infections result from a wide variety of 
bacterial species.  The first bacterial species to typically infect the airways is S. aureus with 
>70% of all CF patients being colonized by age 10.28  Airway colonization by S. aureus results 
in increased inflammation and low body mass index of infants with CF.29  Colonization with 
organisms within the Burkholderia cepacia complex (BCC) is relatively low (i.e., 3.5% versus 
80% colonization by P. aeruginosa in adult CF patients).30  However, the pathogenicity of BCC 
species is high and has been linked to the development of necrotizing pneumonia (frequently 
termed “cepacia syndrome”), sepsis, and death.30-31  The pathogenicity of BCC species is 
furthered by high incidences of antibiotic resistance as a result of their enhanced biofilm 
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formation, anaerobic growth capacity, and unusual lipopolysaccharide composition.  Currently, 
BCC infections are treated by co-administration of antibiotics with limited success.30-31 
 The susceptibility of these CF pathogens (i.e., S. aureus and BCC organisms) to NO-
releasing chitosan oligosaccharides should be determined under conditions that closely mimic 
CF airways.  While minimum inhibitory assays against planktonic bacteria are used clinically, 
these assays do not reliably predict biofilm susceptibility.32  All bactericidal assays should be 
performed using macrocolony biofilms grown in artificial sputum media (ASM) to better mimic 
in vivo physiological conditions.33  Of note, BCC species do not readily form biofilms in vivo 
and therefore may not form biofilms in ASM.  Regardless, these conditions will most accurately 
mimic the CF airway.34  Finally, assays against BCC should be performed both aerobically and 
anaerobically as BCC are frequently found within the hypoxic zones of the CF mucus layer.34 
5.2.4 Co-administration of nitric oxide-releasing chitosan oligosaccharides with antibiotics 
 Additive or synergistic activity between NO and commonly prescribed CF antbiotics may 
increase the effectiveness of antibacterial treatment regimens.  Co-administration of several 
antibiotics is currently used to treat drug-resistant infections, but the success of this approach is 
debated.35-38  Unlike traditional antibiotics that only kill bacteria, the unique biofilm degrading 
capabilities of NO make it uniquely suited for co-administration.  For example, combination 
therapy with the NO donor sodium nitroprusside (SNP) and tobramycin was shown to increase 
P. aeruginosa biofilm eradication in vitro compared to either treatment alone.39  Inhalation of 
NO gas (5-10 ppm for 8 h/day) by CF patients has been demonstrated to reduce bacterial 
biofilms in the airways when combined with antibiotic therapy (i.e., tobramycin or ceftazidime).  
While these results are promising, systematic in vitro studies quantifying the effect of NO (i.e., 
additive or synergistic) are lacking.  Therefore, multiple combination bactericidal antibiotic tests 
170 
 
(MCBT or “checkerboard” assays) should be performed on CF-relevant biofilms. As inhalable 
formulations of tobramycin, aztreonam, and levofloxacin have already been developed, the 
potential synergy between NO-releasing chitosan oligosaccharides and these antibiotics should 
be evaluated first.   As outlined in Section 2.5.4, P. aeruginosa, S. aureus, and BCC biofilms are 
the most clinically relevant organisms and therefore should be evaluated under aerobic and 
anaerobic conditions.   
Section 5.3 Conclusions 
 This dissertation describes the potential utility of NO-releasing chitosan oligosaccharides 
to both eradicate P. aeruginosa biofilms and alter the biophysical properties of CF mucus.  Nitric 
oxide-releasing chitosan oligosaccharides exhibit several advantages over tobramycin as 
antibacterial agents.  First, the antibacterial efficacy of NO-releasing chitosan oligosaccharides 
was enhanced under anaerobic conditions due to reduced reactions with oxygen (i.e., oxygen 
scavenging) in the media.   In addition to eradicating P. aeruginosa biofilms, NO was shown to 
degrade the physical properties of the biofilm while tobramycin failed to alter the rheological 
properties of P. aeruginosa biofilms.  By reducing the biofilm viscoelasticity, NO-releasing 
chitosan oligosaccharides may improve the ability to clear infections, particularly as the physical 
properties of CF mucus dictate disease pathogenesis.   
Nitric oxide-releasing chitosan oligosaccharides clearly alter the physical properties of 
HBE mucus and CF sputum, indicating NO’s potential as a mucolytic agent.  For example, NO 
released from mucoadhesive scaffolds increased mucin migration during electrophoretic 
separation, altered mucin networks in CF sputum, and decreased the viscous and elastic moduli 
of CF sputum.  The chitosan oligosaccharide scaffold also significantly altered the biophysical 
properties of CF mucus components.  While the cationic nature of the chitosan oligosaccharides 
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increases the scaffold mucoadhesion and NO’s mucolytic efficacy, it also negatively impacts (i.e. 
increases) the elasticity of P. aeruginosa biofilms.  Future experiments should determine the 
relative contributions of bacterial biofilms and mucus to the rheological properties of infected CF 
sputum to further guide the development of NO-releasing scaffolds as CF therapeutics.  While 
this dissertation research represents an initial step, it also provides motivation for the 
development of NO-releasing materials as dual-action antibacterial and mucolytic therapies for 
the treatment of CF.   
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